Draft – Not for Implementation

Pulse Oximeters for Medical Purposes - Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations

Draft Guidance for Industry and Food and Drug Administration Staff

DRAFT GUIDANCE

This draft guidance document is being distributed for comment purposes only.

Document issued on January 7, 2025.

You should submit comments and suggestions regarding this draft document within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <u>https://www.regulations.gov</u>. Submit written comments to the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane, Room 1061, (HFA-305), Rockville, MD 20852. Identify all comments with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions about this document, contact OHT1: Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices/DHT1C: Division of Anesthesia, Respiratory, and Sleep Devices at (301) 796-5620.

When final, this guidance will supersede Pulse Oximeters – Premarket Notification Submissions [510(k)s], issued March 4, 2013.



U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health

Draft – Not for Implementation

Preface

Additional Copies

Additional copies are available from the Internet. You may also send an email request to <u>CDRH-Guidance@fda.hhs.gov</u> to receive a copy of the guidance. Please include the document number GUI00001605 and complete title of the guidance in the request.

Table of Contents

I.	Introd	uction	1
II.	Backg	round	2
III.	Scope		4
IV.	Prema	rket Submission Recommendations	8
А	. Dev	ice Description	8
В	. Prec	dicate Comparison (Devices reviewed under 510(k))	9
С	. Lab	eling	
	(1)	For All Pulse Oximeters	11
	(2)	For Prescription Pulse Oximeters	15
	(3)	For OTC Pulse Oximeters	17
	(4)	For Pulse Oximeters That Were Previously 510(k)-cleared	18
D		ility	
E	. Rep	rocessing	19
	(1)	For Submissions of Reprocessed Single-Use Sensors, when applicable	20
F		If Life and Packaging	
G	. Bio	compatibility	21
Η	. Soft	tware	23
I.	Cyb	persecurity	24
J.	Hur	nan Factors	24
Κ	. Elec	ctrical Safety and Electromagnetic Compatibility (EMC)	25
L	. Wir	eless Technology	26
Ν	I. Mag	gnetic Resonance (MR) Compatibility	27
Ν	. Nor	n-Clinical Bench Testing	27
	(1)	SpO2 accuracy for oximeters labeled for use in low perfusion conditions	28
	(2)	Pulse rate accuracy	28
	(3)	Pulse rate accuracy for oximeters labeled for use during motion conditions	28
	(4)	Pulse rate accuracy for oximeters labeled for use in low perfusion conditions	29
	(5)	Alarms	29
	(6)	Display values, outputs and indicators	29
	(7)	Saturation pulse information signal, if applicable	30
0	. Clir	ical Performance Testing	30

	(1)	Controlled Desaturation Laboratory Study	31
	(2) young	Additional considerations for pulse oximeters intended for pediatric populations ger than 12 years of age	37
V.	Modif	fications (for previously 510(k)-cleared or authorized devices)	39
App	endix A	A. Example of Labeling for Pulse Oximeters	41
App	endix I	B. Considerations for Printing Monk Skin Tone Color Charts	43

Pulse Oximeters for Medical Purposes - Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations

Draft Guidance for Industry and Food and Drug Administration Staff

8 . 9

1

2

3

4

5 6

7

10

11

12

13

14

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page.

15 I. Introduction

This draft guidance document provides recommendations regarding non-clinical and clinical 16 performance testing of pulse oximeters for medical purposes, including devices with a pulse 17 18 oximeter function that estimates the amount of oxygen in arterial blood and pulse rate. Pulse 19 oximeters are widely used by many types of healthcare providers and lay-users to obtain an 20 indirect measure of arterial blood oxygen saturation. Pulse oximetry is a non-invasive and quick 21 alternative to arterial puncture with blood gas analysis (CO-oximetry). These recommendations 22 are being made based in part on concerns that the accuracy of pulse oximeters can be affected by, among other factors, a person's skin pigmentation.¹ The recommendations are being provided to 23 24 inform the performance evaluation for these devices, to support premarket submissions, 25 regardless of submission type, and to promote consistency and facilitate efficient review of these submissions. Among other topics, the guidance also provides recommendations for labeling, 26 27 which are intended to promote the safe and effective use of pulse oximeters and help users understand the benefits and risks associated with the use of the device. 28

¹ See November 1, 2022: Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee Meeting Announcement and materials, <u>https://www.fda.gov/advisory-committees/advisory-committee-calendar/november-1-2022-anesthesiology-and-respiratory-therapy-devices-panel-medical-devices-advisory#event-materials</u>

29

- 30 For the current edition of the FDA-recognized consensus standards referenced in this document,
- 31 see the <u>FDA Recognized Consensus Standards Database</u>. If submitting a Declaration of
- 32 Conformity to a recognized standard, we recommend you include the appropriate supporting
- 33 documentation. For more information regarding use of consensus standards in regulatory
- 34 submissions, refer to the FDA guidance titled "Appropriate Use of Voluntary Consensus
- 35 <u>Standards in Premarket Submissions for Medical Devices.</u>"
- 36

37 In general, FDA's guidance documents do not establish legally enforceable responsibilities.

38 Instead, guidances describe the Agency's current thinking on a topic and should be viewed only

- 39 as recommendations, unless specific regulatory or statutory requirements are cited. The use of
- 40 the word *should* in Agency guidances means that something is suggested or recommended, but
- 41 not required.
- 42

43 II. Background

44 Current scientific evidence from laboratory desaturation studies^{2, 3} suggests that there are

- 45 accuracy differences in some pulse oximeters, especially in lower arterial blood oxygen
- 46 saturations (SaO₂), between lightly and darkly pigmented individuals. Pulse oximeters are widely
- 47 used to obtain an indirect measure (SpO₂) of arterial blood oxygen saturation (SaO₂). An

48 observed association of a variable with pulse oximeter accuracy does not always imply causation

- and may be observed for a number of reasons. FDA has engaged in numerous efforts to learn
- 50 more about sources of variation in pulse oximeter accuracy and to share information regarding 51 pulse oximeters with the public.
- 52

As part of these efforts, FDA has engaged interested parties regarding how the Agency can help to ensure patients have access to high-quality, safe, and effective pulse oximeters intended for medical purposes.

56 57

58

59

60

- On February 19, 2021, FDA issued a safety communication⁴ informing patients and health care providers that although pulse oximetry is useful for estimating blood oxygen levels, pulse oximeters have limitations and a risk of inaccuracy which, under certain circumstances, should be considered. FDA's safety communication stated that multiple factors may affect the performance of a pulse oximeter's readings, such as poor
- 62 circulation, skin pigmentation, skin thickness, skin temperature, current tobacco use, and
 63 use of fingernail polish.
- 64

² Bickler PE, Feiner JR, Severinghaus JW. Effects of skin pigmentation on pulse oximeter accuracy at low saturation. Anesthesiology. 2005;102.4:715-719.

³ Okunlola OE, Lipnick MS, Batchelder PB, Bernstein M, Feiner JR, Bickler PE. Pulse Oximeter Performance, Racial Inequity, and the Work Ahead. Respir Care. 2022;67(2):252-257.

⁴ Available at <u>https://public4.pagefreezer.com/content/FDA/20-02-2024T15:13/https://www.fda.gov/medical-devices/safety-communications/pulse-oximeter-accuracy-and-limitations-fda-safety-communication</u>

Draft – Not for Implementation

- In 2022, as part of the Centers of Excellence in Regulatory Science and Innovation
 (CERSI) program, FDA partnered with the University of California San Francisco to
 conduct a prospective clinical study of pulse oximeter errors in adult hospitalized patients
 with varying skin pigmentation.⁵ The study was also designed to assess the extent to
 which factors such as low perfusion may impact the accuracy of pulse oximeter readings.
- 70 71

72 73

74

75

76

77

78

• In 2022, as part of the CERSI program, FDA partnered with Stanford University to conduct a prospective clinical study to evaluate the accuracy of pulse oximeters in children.⁶ The study was designed to evaluate pulse oximeter performance in hospitalized pediatric patients (21 years old and younger) of different skin pigmentation levels by assessing the level of error in SpO₂ readings. The study was also designed to assess the extent to which factors such as low perfusion may have an impact on the accuracy of pulse oximeter readings.

- 79 On November 1, 2022, FDA convened the Anesthesiology and Respiratory Therapy • 80 Devices Panel of the Medical Devices Advisory Committee ("2022 Panel").⁷ The 2022 81 Panel members indicated that the currently available clinical evidence for prescription 82 pulse oximeters showed performance differences (hereinafter referred to as "disparate 83 performance") in patients with dark skin pigmentation (as compared to patients with light 84 skin pigmentation), which causes increased risk for the patient for their given disease 85 outcome. The 2022 Panel also indicated that factors other than skin pigmentation, 86 including but not limited to low perfusion, explain some of the disparate performance and 87 should be examined. To address these concerns, the 2022 Panel recommended 88 standardization of skin pigmentation assessment. The 2022 Panel recommended that, overall, pulse oximeters for clinical use should be more accurate and proposed reducing 89 90 the Accuracy Root Mean Square (Arms)⁸ threshold. 91
- On November 16, 2023, FDA issued a discussion paper, "Approach for Improving the Performance Evaluation of Pulse Oximeter Devices Taking Into Consideration Skin Pigmentation, Race and Ethnicity."⁹ In the discussion paper, FDA requested public comment on a series of questions related to an approach to improve the quality of premarket studies and associated methods used to evaluate the performance of pulse oximeters, taking into consideration a participant's skin pigmentation and participant-

⁵ For more information, see <u>https://www.fda.gov/science-research/advancing-regulatory-science/prospective-clinical-study-pulse-oximeter-errors-adult-hospitalized-patients-varying-skin</u> ⁶ For more information, see <u>https://www.fda.gov/science-research/advancing-regulatory-science/prospective-</u>

⁶ For more information, see <u>https://www.fda.gov/science-research/advancing-regulatory-science/prospective-clinical-study-evaluate-accuracy-pulse-oximeters-children</u>

⁷ See November 1, 2022: Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee Meeting Announcement and materials, <u>https://www.fda.gov/advisory-committees/advisory-committee-calendar/november-1-2022-anesthesiology-and-respiratory-therapy-devices-panel-medical-devices-advisory#event-materials</u>

⁸ A_{rms} is the root mean square deviation between SpO₂ and SaO₂ across all paired repeated measures and study participants. See ISO 80601-2-61 *Medical electrical equipment – Part 2-61: Particular requirements for basic safety and essential performance of pulse oximeter equipment* for formula used for determination of A_{rms}. ⁹ Available at https://www.fda.gov/media/173905/download

Draft – Not for Implementation

98 99 100	reported race and ethnicity. The discussion paper continued FDA's efforts to be transparent and informative about how the Agency regulates pulse oximeters intended for medical purposes. ¹⁰
100	medical purposes.
101	• On February 2, 2024, the Anesthesiology and Respiratory Therapy Devices Panel of the
102	Medical Devices Advisory Committee ("2024 Panel") was convened and asked to discuss
104	a proposed approach to improve the quality of premarket studies and associated methods
105	used to evaluate the performance of pulse oximeters submitted for premarket review,
106	taking into consideration a participant's skin pigmentation and participant-reported race
107	and ethnicity. ¹¹ The 2024 Panel was also asked to discuss the type and amount of data
108	that should be provided by manufacturers to FDA to evaluate the performance of pulse
109	oximeters submitted for premarket review, including for prescription and
110	nonprescription, over-the-counter (OTC) indications, and to discuss various labeling
111	considerations. After discussing the advantages and challenges, the 2024 Panel was in
112	general agreement with the approach proposed by FDA.
113	
114	FDA considered comments from the two Panels and discussion paper and incorporated the
115	feedback as appropriate in developing this guidance.

116

117 **III. Scope**

118 The scope of this document is limited to certain pulse oximeters intended for medical

119 purposes,¹² including devices with a pulse oximeter function to estimate the amount of oxygen

120 in arterial blood and pulse rate. The scope of this guidance includes such pulse oximeters when

121 they are: (1) standalone; or (2) included as part of a multi-parameter device. Pulse oximeters

122 may be regulated under the following classification regulations and the scope of this document 123 includes the existing product codes listed in Table 1 below:

124

125 21 CFR 870.2700 Oximeter: An oximeter is a device used to transmit radiation at a
126 known wavelength(s) through blood and to measure the blood oxygen saturation based
127 on the amount of reflected or scattered radiation. It may be used alone or in conjunction
128 with a fiberoptic oximeter catheter.

 $^{^{10}}$ As used in this document, "intended for medical purposes" means that the pulse oximeter is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease and, therefore, meets the definition of "device" set forth in section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

¹¹ See February 2, 2024: Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee Meeting Announcement and materials, <u>https://www.fda.gov/advisory-committees/advisory-committeecalendar/february-2-2024-anesthesiology-and-respiratory-therapy-devices-panel-medical-devices-advisory</u> ¹² See footnote 10.

Draft – Not for Implementation

21 CFR 870.2705¹³ Infant pulse rate and oxygen saturation monitor for over-the-counter 130 131 use: An infant pulse rate and oxygen saturation monitor for over-the-counter use is a 132 device that uses photoplethysmography to measure pulse rate and oxygen saturation in 133 infants. The device may contain alarms that alert the caregiver when vital sign(s) go 134 outside preset threshold(s).

136 21 CFR 870.2710 Ear oximeter: An ear oximeter is an extravascular device used to transmit light at a known wavelength(s) through blood in the ear. The amount of 138 reflected or scattered light as indicated by this device is used to measure the blood oxygen saturation.

140 141

139

135

137

Table 1. Device Types within the Scope of this Guidance.		
Product Code	Product Code Name	Regulation Number
DQA	Oximeter	21 CFR 870.2700
NLF	Oximeter, Reprocessed	21 CFR 870.2700
OLK	Pulse Oximeter for Over-the-	21 CFR 870.2700
	Counter Use	
QYU	Infant Pulse Rate and Oxygen	21 CFR 870.2705
	Saturation Monitor for Over-	
	The-Counter Use	
DPZ	Oximeter, Ear	21 CFR 870.2710

ти 1 р • т

142

Although the product codes listed above are current as of the date of issuance of this guidance, 143

144 new product codes or classification regulations may be created and could fall within the scope

145 of this guidance. We recommend that you reference the product code database

146 (http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm) or contact OHT1:

Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices if you are uncertain 147

148 whether this guidance applies to your device and the product code for your device is not already

149 identified in this guidance. Some of the recommendations in this guidance may assist in

150 complying with some of the special controls for infant pulse rate and oxygen saturation

monitors for OTC use (product code OYU). For information regarding these special controls, 151

- see FDA's website.¹⁴ 152
- 153

This guidance does not address oximeters under product codes OCH (oximeter, infrared, 154

sporting, aviation), or PGJ (oximeter, wellness).¹⁵ In addition, this guidance does not address 155

156 oximeters under product codes MUD (tissue saturation oximeter), NMD (reprocessed tissue

157 saturation oximeter), OEM (cerebral oximeter), or MMA (fetal pulse oximeter).

¹⁴ See classification order, available at <u>https://www.accessdata.fda.gov/cdrh_docs/pdf22/DEN220091.pdf</u>

¹³ This classification regulation includes special controls established in the classification order, available at https://www.accessdata.fda.gov/cdrh_docs/pdf22/DEN220091.pdf. The publication of this classification in the Federal Register and codification in the Code of Federal Regulations is currently pending.

¹⁵ Oximeters in product codes OCH and PGJ are not reviewed or evaluated by the Agency prior to being available to the public at this time because they are intended for general wellness purposes.

Draft – Not for Implementation

158

159 The classification regulations 21 CFR 870.2700, 21 CFR 870.2705, and 21 CFR 870.2710

160 include devices using reflectance, transmittance, and fiber optic technologies, which are

161 collectively referred to as pulse oximeters for the purpose of this guidance. The terms

162 "transmittance" and "reflectance" refer to the sensor geometry and are not related to the

163 principles of pulse oximetry and how the light is absorbed by hemoglobin when placed on intact

skin. A pulse oximeter operates as a system typically composed of a sensor for application over intact skin, an extender cable, and a module or a specific pulse oximeter monitor.¹⁶

165 intact 166

167 This guidance document pertains to non-invasive pulse oximeters to estimate arterial blood

168 oxygen saturation and pulse rate based on the amount of transmitted, reflected and scattered

169 light through various application sites (including, but not limited to finger, ear, foot, hand,

forehead, back, and nose). These pulse oximeters could be indicated for OTC or prescription

171 use. These pulse oximeters could be continuous or spot-checking devices and either standalone

172 or a function within a multi-parameter device. A multi-parameter device which includes a pulse

173 oximeter may be classified under different classification regulations.¹⁷ The pulse oximeters

174 described in this guidance are typically labeled with a general indication for non-invasive

175 measurement of blood oxygen saturation. A manufacturer that wishes to seek a specific clinical

176 indication for use of a pulse oximeter, for example to screen for or diagnose a specific disease

or condition, should submit clinical data to support the safety and effectiveness of the device forthe specific indication.

178 179

180 In addition, pulse oximetry may be an "other function," as that term is used in the FDA

181 guidance "<u>Multiple Function Device Product: Policy and Considerations</u>," which may impact

182 the device "function-under-review" of a multiple function device product. For example, a

183 general wellness¹⁸ pulse oximeter function may provide input data for a device software

184 function that is used to notify the user of a medical condition or event, such as a sleep apnea

185 event. The recommendations described in the aforementioned guidance should also be

186 considered when preparing the documentation for a premarket submission for such a multi-

187 function device product. This guidance may be informative for evaluation and review of pulse

188 oximetry as an "other function" of such a product, which may impact the device "function under 189 review."

190

191 This guidance provides recommendations regarding non-clinical and clinical performance testing

and other information to support premarket submissions for pulse oximeters, regardless of

193 submission type.¹⁹ Because we anticipate that the majority of pulse oximeter premarket

¹⁶ In this guidance, the Agency is using the terms "pulse oximeter" and "pulse oximeter system(s)" interchangeably. ¹⁷ See, e.g., 21 CFR 870.2300, 21 CFR 870.2340.

¹⁸ For more information on general wellness products, see FDA's guidance "<u>General Wellness: Policy for Low Risk</u> <u>Devices</u>."

¹⁹ We note that some of the information recommended by this guidance could also be a requirement of the submission type appropriate for a specific new device, including a requirement of a class II device's special controls. Alternatively, the recommendations could help manufacturers comply with any applicable premarket submission requirements and/or special controls.

Draft – Not for Implementation

194 submissions will be premarket notification (510(k)) submissions, the guidance document is

tailored to describe the recommended information to be included to support 510(k)

196 submissions.²⁰ However, the guidance provides recommendations which may also be applicable

197 to pulse oximeters that are reviewed via the De Novo classification²¹ or Premarket Approval

198 pathways.²² This guidance document supplements other FDA documents regarding the specific

199 content requirements and recommendations of premarket submissions.

200

For both new and currently-marketed pulse oximeters intended for medical purposes within the

scope of this guidance, including previously-cleared pulse oximeters that are modified in ways that require a new 510(k), FDA recommends that manufacturers gather clinical data, consistent

204 with the guidance recommendations, to evaluate whether device performance across skin

205 pigmentation levels is non-disparate.²³ For recommendations on clinical performance testing that

206 apply to both new and currently-marketed pulse oximeters, see Section IV.O.

207

FDA is also updating its recommendations concerning the content and format of certain labeling information for pulse oximeters, as originally described in the 2013 guidance document,²⁴ based

information for pulse oximeters, as originally described in the 2013 guidance document,²⁴ based in part on concerns about the disparate performance of pulse oximeters as outlined above. For all

new pulse oximeters for medical purposes, see labeling recommendations in Section IV.C(1) -

(3), including labeling recommendations for when non-disparate performance has been

213 demonstrated (as recommended in Section IV.O). For further recommendations on labeling and

510(k) submission²⁵ for pulse oximeters for medical purposes that were previously 510(k)-

215 cleared,²⁶ see Section IV.C(4). FDA intends to publicly communicate on FDA's website through

216 maintaining a list of pulse oximeters that are labeled as having demonstrated non-disparate

- 217 performance after clearance of 510(k) submissions.
- 218 219

²⁰ For more information on premarket notification submissions, refer to 21 CFR 807.87 and FDA's guidance "Electronic Submission Template for Medical Device 510(k) Submissions."

²¹ For devices with a pulse oximeter function that are reviewed via the De Novo classification pathway, refer to 21 CFR 860.220 and FDA's guidance "<u>De Novo Classification Process (Evaluation of Automatic Class III</u> <u>Designation</u>)."

²² For devices with a pulse oximeter function that are reviewed via the Premarket Approval pathway, refer to 21 CFR 814.20 and PMA guidance documents available at <u>https://www.fda.gov/medical-devices/premarket-approval-pma/pma-guidance-documents</u>

²³ See Section IV.O(1)g.ii for the recommended success criteria for non-disparate performance. For purposes of labeling recommendations, which are in Section IV.C, non-disparate performance is described as demonstrating that the pulse oximeter performs comparably across groups of individuals with diverse skin pigmentation.
²⁴ See FDA guidance "Pulse Oximeters - Premarket Notification Submissions [510(k)s]."

²⁵ See 21 CFR 807.81. For further guidance on modifications that trigger the requirement that a manufacturer submit a new 510(k) to the FDA, refer to FDA's guidance "Deciding When to Submit a 510(k) for a Change to an Existing Device."

²⁶ The recommendations also apply to pulse oximeters that were previously authorized through the De Novo classification pathway.

220 IV. Premarket Submission Recommendations

221 A. Device Description

We recommend you identify your device by the applicable classification regulation number and
 product code indicated in Section III above and include the information described below.

We recommend you describe the general purpose or function of the pulse oximeter, including if the device (and accessories) is intended:

- 227 228 as a stand-alone device or a multi-parameter module; • 229 for use in spot-checking, continuous real-time monitoring or continuous data archiving; • 230 for prescription or OTC use; • 231 for use in specific patient population(s); • 232 for low perfusion conditions; • 233 for in-motion conditions (e.g., walking, fidgeting); • 234 for single use or multi-use; • for out-of-hospital transport; and/or 235 • 236 for home use. ٠ 237 We recommend that you identify and describe the device design, including the following: 238 239 240 scientific principles underlying how the device achieves its intended use (e.g., functional •
- sensor configuration/geometry (e.g., reflectance vs. transmittance);
- design features (e.g., functions, alarms);

oxygen saturation);

241

- electro-optical components and their specifications;
- description of the means used to determine SpO₂ and other device outputs from detected optical signals, including processing features intended to evaluate and optimize signal quality, remove noise (e.g., use of numerical/computational methods, machine learning/artificial intelligence routines), and, if applicable, correct for confounding factors including epidermal melanin content;
- description of outputs provided for the user to assess data quality, including range of
 percent modulation for accurate pulse oximeter performance;
- recommended application sites and relevant anatomical dimension(s);
- all patient interface accessories (e.g., patient cable, extender cables, sensors, bandages);
- whether the device and accessories will be provided sterile;
- whether the device is a reprocessed single-use device; and
- device setup and operation information.

Draft – Not for Implementation

257

We also recommend you include drawings, diagrams, or photographs of your device that can help explain the function or highlight new features that may affect safety and effectiveness, for

260 example, changes to a sensor.

261

B. Predicate Comparison (Devices reviewed under 510(k))

263 For devices reviewed under the 510(k) process, manufacturers must demonstrate that their new 264 device is substantially equivalent to a legally marketed predicate device (sections 513(f)(1) and 513(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act); 21 CFR 807.87(f)). This 265 266 comparison should provide information to demonstrate how your device is similar to and 267 different from the predicate. Side by side comparisons, whenever possible, are desirable. See 268 Table 2 below for an example of how this information might be organized. This table is not 269 intended to represent an exhaustive list of comparative parameters; we recommend you provide 270 all relevant device descriptive characteristics as outlined in the "Device Description" section, 271 above.

272

Table 2. Sample predicate comparison table to outline differences and similarities between the subject and predicate device.

Description	Subject Device	Predicate Device (Kxxxxx)
Intended use (see Section IV.A. above)		
Indications for use, including a description of the patient population for which the device is intended (e.g., neonate, infant, pediatric, adult)		
Intended application site (e.g., finger, ear, foot, hand, forehead, back, nose)		
Electro-optical components and their specifications		
Description of algorithm		
Performance specifications (including use under motion and low perfusion conditions, if applicable, and any indices or signals provided to the user)		
Performance across populations with diverse skin pigmentation ²⁷		

²⁷ For information regarding this parameter, refer to Section IV.O(1).

Safety specifications (e.g., electrical, mechanical, environmental)	
Features/design specifications (e.g., alarms, display and indicators, modes)	
Sterility/reprocessing status	
Other relevant characteristics	

275

276 **C. Labeling²⁸**

The premarket notification must include proposed labeling in sufficient detail to satisfy the requirements of 21 CFR 807.87(e). Proposed labels, labeling, and advertisements sufficient to describe the pulse oximeter, its intended use, and the directions for use must be provided in a premarket submission. FDA is including labeling recommendations for manufacturers of pulse oximeters that were previously 510(k)-cleared and all new pulse oximeters within the scope of this guidance.

283

For Prescription Use: As a prescription device, a pulse oximeter is exempt from the requirement 284 to have adequate directions for use²⁹ required under section 502(f)(1) of the FD&C Act if the 285 286 conditions in 21 CFR 801.109 are met. To be so exempt, labeling that furnishes information for 287 use of the prescription device must, among other things, contain "adequate information for such 288 use, including indications, effects, routes, methods, and frequency and duration of administration 289 and any relevant hazards, contraindications, side effects, and precautions, under which 290 practitioners licensed by law to employ the device can use the device safely and for the purposes 291 for which it is intended" (21 CFR 801.109(d)). In addition, the label of the device must bear 292 "[t]he symbol statement 'Rx only' or '<u>R</u> only' or the statement 'Caution: Federal law restricts 293 this device to sale by or on the order of a ', the blank to be filled with the word 'physician,' 294 'dentist,' 'veterinarian,' or with the descriptive designation of any other practitioner licensed by 295 the law of the State in which the practitioner practices to use or order the use of the device" (21 296 CFR 801.109(b)(1)).

297

298 For OTC Use: As an OTC device, under section 502(f) of the FD&C Act and 21 CFR 801.5, the

device labeling must include adequate directions for use. The labeling (e.g., package insert) must

describe the intended use of the device and include a listing of all conditions, purposes, or uses

- for which it is recommended, suggested, or commonly used (21 CFR 801.5(a)). The labeling
- 302 recommendations below are not intended to capture all possible limitations or instructions for all 303 pulse oximeters. Therefore, when developing your labeling, it may be necessary for you to
- include additional limitations (e.g., contraindications, warnings, precautions, adverse reactions),
- 305 and other instructions that are appropriate for your device, depending on its specific design,

²⁸ We note that other labeling recommendations are provided in other sections of this guidance as well (e.g., reprocessing).

²⁹ Adequate directions for use means directions under which the layman can use a device safely and for the purposes for which it is intended (21 CFR 801.5).

Draft – Not for Implementation

306 features, and performance characteristics, and depending on the results and conclusions drawn 307 from a usability study, if applicable.

308

309 Accurate, clear device labeling can help mitigate performance issues associated with pulse

310 oximeters and is important to make users aware of the risks, limitations, and directions for use of

311 pulse oximeters. Moreover, a device shall be deemed misbranded if, among other things: its

312 labeling is false or misleading; its labeling does not contain adequate warnings; or any

313 information required to be in the labeling is not prominently placed with such conspicuousness 314 and in such terms to render it likely to be read and understood by the ordinary individual under

315 customary conditions of purchase and use (see sections 201(n), 502(a), 502(c), and 502(f)(2) of

316 the FD&C Act). As always, FDA will make case-by-case decisions regarding the enforcement of

317 legal requirements in response to particular circumstances and questions that arise regarding a

318 specific device. This may include FDA requesting a firm initiate a recall (see 21 CFR 7.45) or

319 taking other actions, including an enforcement action.

320

321 This section includes recommended labeling content for pulse oximeters within the scope of this 322 document, as outlined in the following sub-sections: (1) all pulse oximeters (i.e., prescription and 323 OTC); (2) additional labeling specific to prescription pulse oximeters; (3) additional labeling 324 specific to OTC pulse oximeters; and (4) additional labeling specific to pulse oximeters that were 325 previously 510(k)-cleared.

- 326
- 327

(1) For All Pulse Oximeters

328 To help manufacturers develop appropriate labeling, FDA recommends that the following 329 labeling content be included for prescription and OTC pulse oximeters within the scope of this 330 guidance. FDA also recommends that you follow the labeling considerations referenced in the 331 currently FDA-recognized version of the consensus standard ISO 80601-2-61 Medical electrical 332 equipment – Part 2-61: Particular requirements for basic safety and essential performance of 333 pulse oximeter equipment.

- 334
- 335

a. Package Labeling

336 Consistent with recommendations shared at the 2024 Panel Meeting,³⁰ FDA recommends that

337 the package labeling for prescription and OTC pulse oximeters include a prominent statement 338 that the pulse oximeter is intended for medical purposes.³¹

339

340 Furthermore, if the manufacturer submits clinical data in a new 510(k) showing non-disparate

- 341 performance (see Section IV.O), we recommend that you include a prominent statement in the
- package labeling and package insert, such as "This pulse oximeter has been evaluated to perform 342

³⁰ See February 2, 2024: Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee Meeting Announcement and materials, https://www.fda.gov/advisory-committeecalendar/february-2-2024-anesthesiology-and-respiratory-therapy-devices-panel-medical-devices-advisory ³¹ To verify whether a specific device has been cleared/granted/approved for marketing authorization by FDA,

please refer to FDA databases, such as https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm.

343 344 345	comparably across groups o provided consistent with the	f individuals with a wide variety of skin tones based on [details study conducted]." ³²
346	b. Pac	kage Insert Labeling
347 348 349	FDA recommends that the p applicable.	ackage insert labeling include the following information, where
350 351 352 353 354 355 356	Section IV.O), we recomme as "This pulse oximeter has	-Disparate Performance arate performance has been demonstrated in a new 510(k) (see nd that you include a prominent statement in the package insert, such been evaluated to perform comparably across groups of individuals ones based on [details provided consistent with the study
357	Indications for Use	
358	• Statement of all con	nditions, purposes, or uses for which the device is intended, such as;
359	• for use as a	stand-alone device or a multi-parameter module;
360 361	 for use in sp archiving; 	oot-checking, continuous real-time monitoring or continuous data
362	 for prescription 	tion or OTC use;
363	• for use in sp	pecific patient population(s);
364	 for low perf 	usion conditions;
365	\circ for in motio	n conditions (e.g., walking, fidgeting);
366	• for single us	se or multi-use;
367	○ for out-of-h	ospital transport; and/or
368	• for home us	e.
369		
370	Device Description	
371 372 373	FDA recommends that you information, such as:	include a description of the pulse oximeter identifying important
374 375	• Scientific principles functional oxygen s	s underlying how the device achieves its intended use (e.g., aturation);
376	Sensor configuration	n/geometry (e.g., reflectance vs. transmittance);
377	• Recommended app	lication sites and relevant anatomical dimension(s);

 $^{^{32}}$ The Agency believes that the labeling recommendations in this guidance should be representative of the clinical data collected (as also recommended in this guidance), and that new clinical data supporting labeling changes can be submitted in a new 510(k) submission.

378	• Design features (e.g., functions, alarms);
379	• All patient interface accessories (e.g., patient cable, extender cables, sensors, bandages);
380	• Whether the device and accessories will be provided sterile;
381	• Whether the device is a reprocessed single-use device;
382 383 384	• Description of outputs provided for the user to assess data quality, including range of percent modulation (an indicator of signal quality) for accurate pulse oximeter performance; and
385	Device setup and operation information.
386	
387	Warnings
388 389 390 391	FDA recommends that manufacturers prominently display appropriate warnings in the instructions for use regarding how to avoid known hazards and/or be aware of certain relevant risk or safety information associated with the use of the pulse oximeter. We believe such warnings should inform patients/users of known hazards and other relevant information, such as
392	the following:
393	
394	• Only a health care provider can diagnose medical conditions;
395	• Reliance solely on a pulse oximeter to detect health conditions or blood oxygen levels
396	may delay seeking and receiving of appropriate and timely medical attention;
397	• Pay attention to other signs or symptoms of low oxygen levels;
398 399	• Initiating or increasing therapy due to pulse oximeter readings without consulting a health care provider is not intended and may lead to harm;
400	• Pulse oximeters may not accurately estimate blood oxygenation and there is a range of
401 402	uncertainty about the displayed SpO_2 value as to the true blood oxygenation level. SpO_2 error may increase with decreasing true blood oxygenation level ^{33, 34} ;
403	• Differences in skin pigmentation may cause differences in pulse oximeter sensor
404	performance and thereby impact SpO ₂ readings, especially in very low oxygen levels;
405	• Trends in measurement may be more meaningful than one single measurement;
406	• Not all blood oxygenation values have been verified with clinical performance testing; see
407	overview of performance studies for range of SaO ₂ values tested for this device;
408	• Environmental and physiologic conditions may contribute to poor pulse oximeter
409	performance or adverse events;
410	• Continuous use longer than recommended in the labeling may incur patient injury;
411	• Continuous sensor wear that restrict movement(s) may interfere with normal activity and
412 413	age-appropriate development (e.g., turning over, crawling, standing, walking, playing); and
413 414	 Alarms or alerts may interfere with sleep stages of user and caregiver(s).
414	\bullet marms of along magnitude with sloop slages of used and calegivel(s).

Alarms or alerts may interfere with sleep stages of user and caregiver(s). •

³³ Bickler PE, Feiner JR, Severinghaus JW. Effects of skin pigmentation on pulse oximeter accuracy at low saturation. Anesthesiology. 2005;102.4:715-719. ³⁴ Okunlola OE, Lipnick MS, Batchelder PB, Bernstein M, Feiner JR, Bickler PE. Pulse Oximeter Performance,

Racial Inequity, and the Work Ahead. Respir Care. 2022;67(2):252-257.

415	
416	Examples of the types of warnings that should be included, as listed above, are provided in
417	Appendix A.
418	
419	Precautions
420	We recommend that manufacturers prominently display appropriate precautions in the
421	instructions for use regarding use of the device on patients, including patients with the following
422	conditions:
423	
424	• Hypersensitivity to material intended for patient contact; and
425	• Poor skin integrity at sensor application site(s).
426	
427	Directions for Use
428 429 430 431 432	FDA recommends manufacturers provide clear and simple directions for use to ensure that users understand how to best apply the pulse oximeter sensor for safe and effective device use. FDA recommends providing a complete set of directions for use, including information to address the following:
433	• Instructions for optimizing measurements of oxygen saturation should take into account
434 435	optimal placement (e.g., anatomical site and geometry), conditions, and stable SpO ₂ values, when present;
436 437	• Instructions on how to evaluate/use indicators of signal quality (e.g., percent modulation) and understand the waveform, when present;
438 439	• For accurate SpO ₂ and pulse rate values, instructions to consider signal inadequacy (e.g., due to low signal intensity, unstable readings);
440 441	• Consideration of percent modulation ranges, when available, and methods to improve percent modulation for accurate pulse oximeter performance;
442	• Instructions for the frequency of inspection of the application site for skin integrity;
443	• Instructions for the frequency of sensor relocation to a different measurement site; and
444	• Device service and maintenance information, including cleaning and disinfection
445	instructions for reusable pulse oximeters and accessories.
446	
447	Examples of directions for use that could be included are provided in Appendix A.
448	
449	Magnetic Resonance (MR) Safety Information
450	We recommend you follow the labeling recommendations in FDA's guidance, "Testing and
451	Labeling Medical Devices for Safety in the Magnetic Resonance (MR) Environment." We also
452	recommend using the standardized terminology and icons as described in the currently
453	recognized version of ASTM F2503 Standard Practice for Marking Medical Devices and Other
454	Items for Safety in the Magnetic Resonance Environment.

456	(2) For Prescription Pulse Oximeters
457 458 459 460 461 462	FDA recommends that for prescription pulse oximeters within the scope of this guidance, manufacturers provide in the device labeling an overview of clinical performance studies conducted to determine accuracy and non-disparate performance across populations with diverse skin pigmentation. The labeling should identify the specific models of pulse oximeters with which the sensors were clinically validated and are intended to be used.
463 464	a. Overview of performance studies for all prescription pulse oximeters
465 466 467 468	FDA recommends that you include in the labeling relevant performance information from your controlled desaturation laboratory study (as described in Section IV.O(1)) and non-clinical bench testing (as described in Section IV.N), such as the following:
469 470 471 472 473 474 475	 Demographics of adult study participants – number of participants, sex, age, body mass index (BMI), forehead Monk Skin Tone³⁵ (MST) and Individual Typology Angle³⁶ (ITA) (see definition in Section IV.O(1)b), self-reported ethnicity, self-reported race, relevant sensor site description (e.g., index finger, circumference of finger), emittersensor site ITA, range of desaturation per MST group (see definition in Section IV.O(1)b), and number of data pairs per participant – for all tested pulse oximeter systems;
476 477 478	• SpO_2 Accuracy (A _{rms}) estimate, standard error, and 95% confidence interval (CI) for all tested conditions (e.g., motion, non-motion, low perfusion) overall and stratified by the SaO ₂ deciles, 70% \leq SaO ₂ $<$ 80%, 80% \leq SaO ₂ $<$ 90%, and 90% \leq SaO ₂ \leq 100%;
479 480 481	• Mean and standard deviation of SpO ₂ error (SpO ₂ - SaO ₂) for all tested conditions (e.g., motion, non-motion, low perfusion) overall and stratified by SaO ₂ deciles as stated above;
482 483 484	• SpO ₂ bias (i.e., mean error) estimate, standard error, and 95% CI for all tested conditions (e.g., motion, non-motion, low perfusion) and stratified into the three MST groups (1-4, 5-7, and 8-10) based on evaluation of the forehead;
485 486	• SpO ₂ bias (i.e., mean error) by ITA, across an ITA interval that is representative of the surface(s) intended for contact with the sensor emitter;
487	• Range of percent modulation in study participants undergoing clinical study;
488 489	• Summary of test methods for accurate performance in low perfusion conditions, if applicable;

 ³⁵ Heldreth CM, Monk EP, Clark AT, Schumann C, Eyee X, Ricco S. Which skin tone measures are the most inclusive? An investigation of skin tone measures for artificial intelligence. ACM Journal on Responsible Computing 1, no. 1 (2024): 1-21. MST is a subjective scale comprising ten values to assess skin tones.
 ³⁶ Del Bino S, Bernerd F. Variations in skin colour and the biological consequences of ultraviolet radiation exposure. Br J Dermatol. 2013 Oct;169 Suppl 3:33-40. ITA is an objective, continuous, quantitative measure of skin pigmentation.

490	• Summary of test methods for accurate performance in motion conditions, if applicable;
491 492	• Bench testing pulse rate accuracy specification covering the entire pulse rate display range and summary of test methods;
493	• Operating and storage temperature and humidity; and
494	• Device settings used during performance testing.
495	
496	Bland Altman, ³⁷ modified Bland Altman, ³⁸ Quantile-Quantile (QQ), ³⁹ and inverse prediction
497	plots ⁴⁰ are also recommended to be included in labeling to characterize device performance (i.e.,
498	agreement, bias, and uncertainty).
499	
500	b. Overview of performance studies for prescription pulse oximeters
501	intended for pediatric populations younger than 12 years of age
502	Clinical performance testing of a pulse oximeter system in adult populations may not be
503	sufficient to support clinical performance in certain pediatric subgroups such as neonates,
504 505	infants, and children younger than 12 years of age due to significant differences in form and fit of the pulse oximeter sensor that may lead to differences in overall accuracy of the system. For
505	pulse oximeter systems intended for use in pediatric populations younger than 12 years of age, ⁴¹
507	in addition to the labeling on the controlled desaturation study in adults (see Section IV.C(2)a),
508	we also recommend you include labeling on the convenience arterial sample collection (see
509	Section IV.O(2)). Such labeling should include information regarding each intended pediatric
510	subpopulation – i.e., neonates (birth to 30 days), infants (1 month to less than 2 years), and
511 512	children (2 years to less than 12 years), as applicable, such as the following:
512	• Patient population characteristics of the pediatric population tested: sex, age, weight
514	(percentile), diagnosis and/or comorbidities, forehead MST and ITA, emitter sensor site
515	ITA, reported ethnicity, reported race, relevant sensor site description (e.g., mid-foot,
516	circumference of foot), data pairs per participant;
517	Number of participants;
518	• Number of data samples;

³⁷ Bland JM, Altman DG. Agreement between methods of measurement with multiple observations per individual. J Biopharm Stat. 2007;17(4):571-82.

³⁸ For two measurements Y and X of the same quantity, the Bland-Altman plot is a plot of the difference D = Y - X vs. average A = (Y + X)/2. The modified Bland-Altman plot is a plot of D vs. X.

³⁹ For paired SpO₂ and SaO₂, a QQ plot of SpO₂ vs. SaO₂ is a scatterplot of the ordered values of SpO₂ vs. the ordered values of SaO₂.

⁴⁰ Greenwell BM, Schubert Kabban CM. investr: An R Package for Inverse Estimation. *The R Journal*. 2014 June; 6(1): 90-100.

⁴¹ In the statutory provisions governing the regulation of medical devices, section 520(m)(6)(E)(i) of the FD&C Act defines "pediatric patients" as patients aged 21 or younger at the time of their diagnosis or treatment. FDA generally considers this to be the age from birth through the 21st year of life, up to but not including the 22nd birthday. Pediatric subpopulations are defined in section 520(m)(6)(E)(i) (and adopted by reference in section 515A(c) of the FD&C Act) to be neonates, infants, children, and adolescents.

519 520	 Range of percent modulation in study participants undergoing clinical study; SaO₂ range; and
521 522	• A_{rms} analyses, including estimate, standard error and 95% CI.
523	(3) For OTC Pulse Oximeters
524 525 526 527 528 529 530 531	For OTC pulse oximeters within the scope of this guidance, the labeling should be written in simple, plain language and instruct the end user on how to use the device safely and for the purposes for which it is intended, and to identify any potential risks. When preparing user labeling for OTC pulse oximeters, we recommend following the FDA guidance " <u>Guidance on Medical Device Patient Labeling</u> ," which describes FDA's current thinking on making medical device patient labeling understandable to and usable by patients. FDA recommends that the labeling for OTC pulse oximeters also contain the following additional recommendations for the package insert.
532	a. Directions for Use
533 534 535 536	In addition to directions for use discussed in Section IV.C(1)b, FDA recommends that the package insert include clear and simple directions for safe and accurate use by lay users. We recommend that labeling for OTC pulse oximeters include:
537 538	• Instructions that reference normal physiologic ranges of SpO ₂ for the intended use, intended populations and intended environment of use (e.g., geographic elevation);
539 540	• Instructions for lay users to seek timely medical attention for readings outside normal range(s); and
541 542	• Instructions for lay users on fluctuating SpO ₂ values.
543 544	FDA also recommends that manufacturers also consider including drawings or diagrams in the directions for use for lay users, where appropriate.
545	b. Overview of performance studies for all OTC pulse oximeters
546 547 548 549	For OTC pulse oximeters, FDA recommends that you include in the labeling a clear and simple overview of the controlled desaturation laboratory study (as described in Section IV.O(1)) and non-clinical bench testing (as described in Section IV.N), such as the following:
550 551 552	• Demographics of adult study participants - number of participants, sex, age, weight range, forehead MST of study participants, self-reported ethnicity, self-reported race, relevant sensor site description (e.g., index finger, circumference of finger);
553	• Evidence of an accurately printed MST color chart (see Appendix B for details),
554 555	• Overall accuracy (A _{rms}) and an explanation of the range of SaO ₂ for an SpO ₂ value for all tested conditions (i.e., motion, non-motion);
556 557	 Accuracy stratified by SaO₂ decile: 70% ≤ SaO₂<80%, 80% ≤ SaO₂<90%, and 90% ≤ SaO₂≤ 100%;

558 559	• How the clinical study demonstrated accurate performance across participants with diverse skin pigmentation;		
560	• The confidence with which the validation study meets the success criteria ⁴² ;		
561 562	• If percent modulation is provided in device user interface (UI), the range of percent modulation of study participants during the study;		
563	• Summary of test methods for accurate performance in motion conditions, if applicable;		
564 565	• Bench testing pulse rate accuracy specification covering the entire pulse rate display range and summary of test methods;		
566	Operating and storage temperature and humidity; and		
567	• Device settings used during performance testing.		
568			
569 570	An inverse prediction plot is also recommended to be included in labeling to characterize uncertainty of the blood oxygen level given the pulse oximeter estimate of it.		
571			
572 573	c. Overview of performance studies for OTC pulse oximeters intended for pediatric populations younger than 12 years of age		
574 575 576 577 578 579 580	For pulse oximeter systems intended for use in pediatric populations younger than 12 years of age, in addition to the labeling on the controlled desaturation study in adults (see Section IV.C(3)b), we also recommend you include labeling on the convenience arterial sample collection (see Section IV.O(2)). Such labeling should include information regarding each intended pediatric subpopulation (i.e., neonates (birth to 30 days), infants (1 month to less than 2 years), and children (2 years to less than 12 years)), as applicable, such as the following:		
580 581 582 583 584	• Patient population characteristics of the pediatric population tested (sex, age, weight (percentile), diagnosis and/or comorbidities, forehead MST value, reported ethnicity, reported race, relevant sensor site description (e.g., mid-foot, circumference of foot)); and		
585	• Overall accuracy (Arms)		
586			
587	(4) For Pulse Oximeters That Were Previously 510(k)-cleared		
588 589 590 591 592	Based on concerns about the disparate performance of pulse oximeters that were previously 510(k)-cleared, the Agency recommends that, if not already done so, manufacturers of such cleared devices should gather clinical data (e.g., controlled desaturation laboratory study or "real-world data" (RWD)) to evaluate their pulse oximeter for non-disparate performance (see success criteria ⁴³ 2 and 3 in Section IV.O(1)g.ii), and submit such data to the Agency in a new		

 ⁴² See recommended success criteria for non-disparate performance in Section IV.O(1)g.ii.
 ⁴³ For RWD included as support of non-disparate performance, we recommend that manufacturers also include in the package insert labeling an Arms estimate based on RWD.

Draft – Not for Implementation

510(k) submission.⁴⁴ Where the manufacturer of a previously 510(k)-cleared pulse oximeter has 593 594 updated labeling but not otherwise made significant changes or modifications to their device 595 (e.g., hardware, software), FDA generally intends to complete its review of clinical data related 596 to non-disparate performance within 30 days of receipt of the 510(k) submission. If non-597 disparate performance has been demonstrated in a 510(k), we recommend that package labeling 598 include a prominent statement, such as "This pulse oximeter has been evaluated to perform 599 comparably across groups of individuals with a wide variety of skin tones based on [details 600 provided consistent with the study conducted]." FDA recommends that manufacturers also 601 include such a statement in the 510(k) summary as part of the discussion regarding clinical 602 testing (see 21 CFR 807.92(b)). As part of a new 510(k) submission, manufacturers should also 603 submit the revised device labeling and 510(k) summary to include the clinical data that supports 604 the non-disparate performance. To further promote transparency, FDA intends to publicly 605 communicate on FDA's website through maintaining a list of pulse oximeters that are labeled as 606 having demonstrated non-disparate performance after clearance of 510(k) submissions. 607

D. **Sterility** 608

609 Significance: Pulse oximeters generally come in contact with intact skin and typically are not 610 provided sterile. However, certain pulse oximeters are provided sterile and these devices should 611 be adequately sterilized to minimize infections and related complications.

612

613 Recommendation: For pulse oximeters labeled as sterile, we recommend that you provide

information for the final device in accordance with FDA's guidance "Submission and Review of 614 615 Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as

- 616 Sterile."
- 617

Reprocessing E. 618

619

620 Significance: Many of the patient contacting components of pulse oximeters are reused, and 621 should be adequately cleaned, then disinfected or sterilized between uses to minimize infections 622 while preventing device degradation.

623

624 Recommendation: Instructions on how to reprocess a reusable device are critical to ensure that a

625 device is appropriately prepared for its initial and subsequent uses. For recommendations 626 regarding the development and validation of reprocessing instructions in your proposed device

labeling, refer to FDA's guidance "Reprocessing Medical Devices in Health Care Settings:

627 628 Validation Methods and Labeling."

⁴⁴ See footnote 32.

Draft – Not for Implementation

(1) For Submissions of Reprocessed Single-Use Sensors, when 630 applicable 631 632 If your device includes a reprocessed single-use sensor, we recommend you provide the 633 following additional information: 634 635 electro-optical specifications of the reprocessed sensors; • 636 means to ensure each reprocessed device meets these specifications; and • 637 tracking methods used to limit the number of reprocessing cycles. • 638 We recommend you provide complete reprocessing methods and validation data⁴⁵ as described 639 in FDA's guidance "Medical Device User Fee and Modernization Act of 2002, Validation Data 640 641 in Premarket Notification Submissions (510(k)s) for Reprocessed Single-Use Medical Devices." This should include, but not necessarily be limited to the following information. 642 643 644 a. Identification of components and uses 645 We recommend you provide a detailed diagram of all the components of the sensors, and 646 identification of each component that will be replaced when the device or system is reprocessed 647 and each component that will be retained. In particular, we recommend you indicate whether the reprocessor will replace or save the laminate that encloses the optical components. 648 649 b. Performance testing 650 651 We recommend you describe the performance testing (e.g., non-clinical bench, clinical 652 performance) conducted to validate the performance of the reprocessed device. We recommend the testing for reprocessed sensors be assessed on worst-case basis (i.e., after the maximum 653 654 number of times the sensor is intended to be reprocessed). In addition, we recommend you 655 simulate use of the sensor after each reprocessing cycle prior to testing. 656 F. **Shelf Life and Packaging** 657

⁴⁵ On October 26, 2002, the Medical Device User Fee and Modernization Act of 2002 (MDUFMA) amended the FD&C Act by adding new section 510(o), which provided new requirements for reprocessed single-use devices (SUDs). According to this provision, to ensure that reprocessed SUDs are substantially equivalent to predicate devices, premarket notification submissions for certain reprocessed SUDs identified by FDA must include validation data. On April 30, 2003, FDA identified a list of those critical reprocessed SUDs that are no longer exempt from 510(k) submission requirements and a list of the non-exempt reprocessed SUDs that are subject to both the 510(k) premarket notification requirement and the validation data submission requirement under MDUFMA (see <u>68 FR</u> <u>23139</u> for original list, <u>68 FR 38071</u> for revised list). In the most recent FR notice (see <u>70 FR 56911</u>), FDA also provided an updated, current listing of all device types subject to these MDUFMA requirements. Reprocessed single-use oximeters are included in *List II: Reprocessed Single-Use Devices Subject to Premarket Notification Requirements That Now Require the Submission of Validation Data*.

Draft – Not for Implementation

658 <u>Significance</u>: Shelf life testing is conducted to support the proposed expiration date through

659 evaluation of the package integrity for maintaining device sterility and/or evaluation of any 660 changes to device performance or functionality.

661

662 Recommendation: With respect to package integrity for maintaining device sterility for devices 663 that are provided sterile, you should provide a description of the packaging, including how it will 664 maintain the device's sterility, and a description of the package integrity test methods, but not the 665 package test data. We recommend that a package validation study include simulated distribution 666 and associated package integrity testing, as well as an aging process (accelerated and/or real-667 time) and associated seal strength testing, to validate package integrity and the proposed shelf life. We recommend you follow the methods described in the FDA-recognized series of 668 669 consensus standards ISO 11607-1 Packaging for terminally sterilized medical devices – Part 1: 670 Requirements for materials, sterile barrier systems and packaging systems and ISO 11607-2

671 Packaging for terminally sterilized medical devices – Part 2: Validation requirements for

- 672 forming, sealing and assembly processes.
- 673

With respect to evaluating the effects of aging on device performance or functionality, shelf life studies should evaluate the critical device properties to ensure the device will perform adequately and consistently during the entire proposed shelf life. To evaluate device functionality, we recommend that you assess each of the bench tests described in Section IV.N and repeat all tests that evaluate design components or characteristics that are potentially affected by aging using

679 aged devices.

680

We recommend that you provide a summary of the test methods used for your shelf life testing,
results and the conclusions drawn from your results. If you use devices subject to accelerated

aging for shelf life testing, we recommend that you specify the way in which the devices were aged and provide a rationale to explain how the results of shelf life testing based on accelerated

aging are representative of the results if the devices were aged in real time. We recommend that

686 you age your devices as described in the currently FDA-recognized version of ASTM F1980

687 Standard Guide for Accelerated Aging of Sterile Barrier Systems and Medical Devices and

688 specify the environmental parameters established to attain the expiration date. For devices or

689 components containing polymeric materials or coatings, you should conduct testing on real-time 690 aged samples to confirm the results of the accelerated aging study. This testing can be conducted

690 aged samples to confirm the results of the accelerated aging study. This testing can be conducted 691 in parallel with 510(k) review, with results documented to file in the design history file (i.e.,

- 692 FDA generally does not expect the results of the real-time testing to be submitted in the 510(k)
- 693 submission).
- 694

695 G. Biocompatibility

696 <u>Significance</u>: Pulse oximeters contain patient-contacting materials, which, when used for their 697 intended purpose (i.e., contact type and duration) may induce a harmful biological response.

698 <u>Recommendation</u>: You should determine the biocompatibility of all patient-contacting

699 components present in your device. If your device is identical in chemical composition,

Draft – Not for Implementation

700 manufacturing and processing methods to pulse oximeters with a history of safe use, you might

reference previous testing experience or the literature, if appropriate. For some device materials,

it may be appropriate to provide a reference to either a recognized consensus standard, or to a

703 Letter of Authorization (LOA) for a device Master File (MAF). You should refer to the

following FDA webpage for additional information on using device MAFs:

705 <u>https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-</u>

- 706 <u>submission/device-master-files</u>.
- 707 If you are unable to identify a legally marketed device with the same nature of contact and
- contact duration that uses the same materials and manufacturing process as is used in your
- 709 device, we recommend you conduct and provide a biocompatibility evaluation as recommended

710 in FDA's guidance "Use of International Standard ISO 10993-1, 'Biological evaluation of

711 <u>medical devices - Part 1: Evaluation and testing within a risk management process.</u>" The

- evaluation should explain the relationship between the identified biocompatibility risks, the
- information available to mitigate the identified risks, and any knowledge gaps that remain. You
- should then identify any biocompatibility testing or other evaluations that were conducted to
- 715 mitigate any remaining risks. The biocompatibility guidance identifies the types of
- biocompatibility assessments that should be considered and provides recommendations regardinghow to conduct related tests.
- 717 718

As described in ISO 10993-1 *Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process* and Attachment A of FDA's guidance on ISO-10993-

1, pulse oximeters are surface devices in contact with intact skin for a prolonged contact

- duration. Therefore, the following endpoints should be addressed in your biocompatibilityevaluation:
- Cytotoxicity;
 - Sensitization; and
- 726

725

• Irritation or intracutaneous reactivity.

727
728 Some test methods for the above endpoints are part of the Accreditation Scheme for Conformity
729 Assessment (ASCA) Program, which can be leveraged by manufacturers to streamline the

review of these test results. For more information, see the ASCA Program website

731

732 This guidance provides recommendations for pulse oximeters that have contact with intact skin.

Additional biocompatibility endpoints might be appropriate to address in your biocompatibility

evaluation if the pulse oximeters have a different type of tissue contact (e.g., mucosal

membrane). Further, additional biocompatibility assessments might be appropriate for pulse

- 736 oximeters intended for certain patient populations (e.g., neonatal or infants).737
- 738 When determining the duration of tissue contact, we recommend that you consider the
- range cumulative use (e.g., total exposure period) of the pulse oximeter. For example, as described in
- ISO 10993-1, the pulse oximeter has prolonged tissue contact if the sum of single, multiple or
- repeated duration of contact exceeds 24 hours but does not exceed 30 days. Of note, the total

exposure period of the device is the number of elapsed calendar days (not number of hours,

minutes or seconds) between first and last use, whether or not the pulse oximeter is used every

day and regardless of the duration of exposure on each day. In addition, we recommend that

745 when designing the biocompatibility tests you consider the cumulative exposure of the pulse 746 oximeter (e.g., extraction conditions, duration of cytotoxicity study, single or repeat exposure for

oximeter (e.g., extraction conditions, duration of cytotoxicity study, single or repeat exposure for
 dermal irritation). You should refer to ISO 10993-12 *Biological evaluation of medical devices* –

748 Part 12: Sample preparation and reference materials for additional details regarding extraction

- 749 conditions and methods.
- 750

751 **H. Software**

<u>Significance</u>: Device software function(s) in pulse oximeters can ensure that the measurement is
 accurate, reliable, and repeatable. Adequate software testing provides assurance the device

- 754 functions as intended.
- 755

756 <u>Recommendation</u>: Refer to the FDA guidance "<u>Content of Premarket Submissions for Device</u>

757 <u>Software Functions</u>" for a discussion of the software information that you should provide in your

submission. The premarket software guidance outlines the recommended information to be

provided in a premarket submission that includes a device software function based on the

⁷⁶⁰ "Documentation Level" associated with the device. We generally consider the device software

function(s) for pulse oximeters to be in the category of a "Basic" Documentation Level.

However, certain indications, applications, or technological characteristics could be in the

763 category of an "Enhanced" Documentation Level. For example, an enhanced documentation

- 764 level is likely appropriate for a pulse oximeter with an alarm to titrate oxygen therapy.
- 765

766 We recommend that you provide a full description of the device software function(s) supporting 767 the operation of the subject device following this premarket software guidance. This

recommendation applies to original devices/systems as well as to any software changes made to

769 previously-cleared devices. Changes to software must be revalidated and reverified in

accordance with Design Controls, 21 CFR 820.30(i), and documented in the Design History File,

21 CFR 820.30(j).⁴⁶ Some software changes may warrant the submission of a new 510(k). For

further information on this topic, refer to "Deciding When to Submit a 510(k) for a Software

773 Change to an Existing Device."

⁴⁶ On February 2, 2024, FDA issued a final rule amending the device quality system (QS) regulation, 21 CFR part 820, to align more closely with international consensus standards for devices. FDA also made conforming amendments to 21 CFR part 4 (<u>89 FR 7496</u>). This final rule will take effect on February 2, 2026. Once in effect, this rule will amend the majority of the current requirements in part 820 and incorporate by reference the 2016 edition of the *International Organization for Standardization (ISO) 13485, Medical devices – Quality management systems – Requirements for regulatory purposes*, in part 820. As stated in the final rule, the requirements in ISO 13485 are, when taken in totality, substantially similar to the requirements of the current part 820, providing a similar level of assurance in a firm's quality management system and ability to consistently manufacture devices that are safe and effective and otherwise in compliance with the FD&C Act. When the final rule takes effect, FDA will also update the references to provisions in 21 CFR part 820 in this guidance to be consistent with that rule.

Draft – Not for Implementation

- 775 If the device includes off-the-shelf software, you should provide the additional information as
- recommended in the FDA guidance documents "Off-the-Shelf Software Use in Medical
- 777 <u>Devices</u>" and "<u>Cybersecurity for Networked Medical Devices Containing Off-The-Shelf (OTS)</u>
- 778 Software," which provide additional information regarding medical devices utilizing off-the-
- shelf software.
- 780

781 If the device is a multiple function device product and includes software function(s) that are

- considered "other functions," as that term is used in the guidance "<u>Multiple Function Device</u>
 <u>Product: Policy and Considerations</u>," the recommendations described in the aforementioned
 guidance should also be considered when preparing the software documentation for a premarket
- 785 submission.
- 786
- 787 Overall, the documentation related to the device software function(s) should provide sufficient
- evidence to describe the role of the software in the context of the device's intended use and
- 789 testing to demonstrate that the software functions as designed.
- 790

791 I. Cybersecurity

<u>Significance</u>: Pulse oximeters could contain software, firmware, or programmable logic, and
 have the ability to connect to the internet either directly or indirectly through the connectivity
 features present in the device design. Failure to maintain cybersecurity can result in risks such as
 compromised device functionality, loss of device availability, loss of data (medical or personal)
 availability or integrity, or exposure of other connected devices or networks to security threats.
 This in turn may have the potential to result in patient injury.

798

799 <u>Recommendation</u>: If the device meets the definition of a cyber device under section 524B(c) of 800 the FD&C Act, cybersecurity documentation under section 524B(b) of the FD&C Act is required 801 as a part of the premarket submission. Refer to the FDA cybersecurity guidance "<u>Cybersecurity</u> 802 <u>in Medical Devices: Quality System Considerations and Content of Premarket Submissions</u>" for 803 a discussion of these requirements and cybersecurity documentation that should be provided in 804 submissions that could help satisfy such requirements.

805

806 J. Human Factors

807 Significance: Use-related hazards are hazards resulting from failure modes tied to the use of 808 pulse oximeters. They are a unique form of hazard in that use-related hazards can exist even if 809 the device operates according to specifications. They generally do not involve specific failure 810 modes associated with faulty electrical, mechanical, and software components that are previously 811 known or reasonably anticipated. To understand the use-related hazards associated with the use 812 of a pulse oximeter, you should consider the device use scenarios (e.g., device users, use 813 environments, and user interface), the tasks within these scenarios that could lead to harm (i.e., 814 critical tasks) and how the device supports the user to complete these tasks in a safe manner. For

815 pulse oximeters, use-related hazards may relate to concerns such as the accurate application of a

Draft – Not for Implementation

816 sensor, user comprehension (e.g., lay-users) of directions for use that influence the accuracy and

- 817 reliability of measurements and adverse events associated with incorrect sensor placement.
- 818

819 <u>Recommendation</u>: Many pulse oximeters sensors are placed on the fingertip, a standard

820 anatomical location for the measurement of SpO₂. To address use-related hazards for all pulse

821 oximeters that are placed in a non-standard anatomical location (i.e., not fingertip), or have

- 822 unique technology and/or features, human factors evaluations should start early in the device
- design process and should occur iteratively. For example, pulse oximeters that are intended to be
- used on the fingertip but are secured in a novel way (e.g., not clip-on) or use different
 technological mechanisms (e.g., reflectance technology rather than transmittance technology)

could be appropriate for a human factors evaluation. There are various methods for the

- preliminary human factors analyses and evaluations, which are discussed further in FDA's
- 828 guidance "Applying Human Factors and Usability Engineering to Medical Devices." The
- guidance also provides recommendations on human factors information included in a premarket
- 830 submission.
- 831

832 In addition, for OTC pulse oximeters intended to be placed in a standard or non-standard

anatomical location, FDA recommends that usability testing (e.g., labeling comprehension) be

834 conducted to identify potential use error and help mitigate sources of error to determine that the

labeling is adequate.⁴⁷ Adequate device labeling can support safe and effective use of these

- 836 devices and are important strategies to address device use hazards.
- 837

K. Electrical Safety and Electromagnetic Compatibility (EMC)

840 <u>Significance</u>: Pulse oximeters are medical electrical equipment and therefore may expose the

- 841 operator and patient to hazards associated with the use of electrical energy or may fail to operate 842 properly in the presence of electromagnetic disturbance.
- 843 <u>Recommendation</u>: Pulse oximeters should be tested to demonstrate that they perform as
- 844 anticipated in their intended use environment. We recommend that this testing be performed as
- 845 described in the currently FDA-recognized versions of the following standards for medical
- 846 electrical equipment safety and electromagnetic compatibility:
- ISO 80601-2-61 Medical electrical equipment Part 2-61: Particular requirements for basic safety and essential performance of pulse oximeter equipment.
- IEC 60601-1 Medical electrical equipment Part 1: General requirements for basic safety and essential performance (with relevant U.S. national differences applied).

⁴⁷ 21 CFR 801.5 states that "*Adequate directions for use* means directions under which the layman can use a device safely and for the purposes for which it is intended." As an OTC device, the device labeling must include adequate directions for use.

Draft – Not for Implementation

 IEC 60601-1-2 Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral standard: Electromagnetic disturbances -Requirements and tests.

854

If submitting a Declaration of Conformity to the above FDA-recognized consensus standards, we recommend that appropriate supporting documentation⁴⁸ be provided. Information regarding test methods chosen and acceptance criteria should be provided because this series of standards includes general methods with multiple options and, in some cases, does not include specific acceptance criteria. For additional information on providing electromagnetic compatibility information in a premarket submission, see FDA's guidance "<u>Electromagnetic Compatibility</u> (EMC) of Medical Devices."

862

863 It should also be noted that the above standards are within the scope of the ASCA Program,

- which can be leveraged by manufacturers to streamline the review of the test results of these
 standards. For more information, see the <u>ASCA Program website</u>.
- 866

867 L. Wireless Technology

<u>Significance</u>: In the design, testing, and use of wireless medical devices, the correct, timely, and
 secure transmission of medical data and information is essential for the safe and effective use of
 medical devices and systems.

871

<u>Recommendation</u>: If your pulse oximeter incorporates radiofrequency wireless technology such
as Bluetooth, IEEE 802.11 (Wi-Fi) or RFID (radio frequency identification) technology, testing
beyond what is described in the IEC 60601 standards is recommended to demonstrate that the
wireless device functions will perform as intended in environments with other wireless products.
For additional recommendations for home use devices with wireless technology, refer to FDA's
guidance "Design Considerations for Devices Intended for Home Use."

878

879 We recommend that you consult FDA's guidance "<u>Radio Frequency Wireless Technology in</u>

880 <u>Medical Devices</u>" for additional recommendations on this topic. When considering risks

associated with wireless coexistence which can arise from multiple wireless systems operating in

- a shared environment, we recommend testing be performed as described in currently FDA-
- 883 recognized versions of the following standards for wireless coexistence:
- 884 885
- AAMI TIR69 Technical Information Report Risk management of radio-frequency wireless coexistence for medical devices and systems; and
- IEEE ANSI USEMCSC C63.27 American National Standard for Evaluation of Wireless Coexistence.
- 887 888

⁴⁸ For more information on Declarations of Conformity and on appropriate supporting documentation, refer to FDA's guidance "<u>Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices</u>."

889 M. Magnetic Resonance (MR) Compatibility

890 <u>Significance</u>: Pulse oximeters that are intended to function during an MR procedure or in the MR
 891 environment pose the following potential hazards for patients:

892

896

897

- Magnetically induced displacement force and/or torque may cause damage by inducing unwanted movement or dislodgement of the pulse oximeter (e.g., a power supply, a monitor);
 - Radiofrequency (RF) of the MR system can induce heating of the tissue adjacent to the pulse oximeter (e.g., a pulse oximeter sensor) and subsequent tissue damage;
- MR interference and the exposure to the MR system's electric and magnetic fields can cause inaccurate oximetry measurement or device malfunction; and/or
- Presence of metallic components can lead to image artifacts in the acquired MR images
 that can render the images uninterpretable or misleading.
- <u>Recommendation</u>: We recommend that you address the issues affecting safety and compatibility
 of your pulse oximeter in the MR environment as described in the FDA guidance "<u>Testing and</u>
 <u>Labeling Medical Devices for Safety in the Magnetic Resonance (MR) Environment.</u>"
- 906

If you would like to market pulse oximeters of various sizes and shapes, then we recommend that
 you follow our recommendations in the FDA guidance "<u>Assessment of Radiofrequency-Induced</u>
 <u>Heating in the Magnetic Resonance (MR) Environment for Multi-Configuration Passive Medical</u>
 Devices."

911

912 N. Non-Clinical Bench Testing

Non-clinical bench testing supports device safety and device performance. Typical bench testing
 should demonstrate that the device functions as intended. To assist in determining the
 appropriate non-clinical bench testing for your device, you can seek input from the Agency via
 the Q-Submission Program.⁴⁹

917

918 For information on the recommended content and format of test reports for the testing described

- 919 in this section, refer to FDA's guidance "<u>Recommended Content and Format of Non-Clinical</u>
 920 Bench Performance Testing Information in Premarket Submissions."
- 921
- 922 Non-clinical bench testing involving patient simulators and/or functional testers (see ISO 80601-
- 923 2-61 describing the definition and appropriate uses of a functional tester) that generate simulated
- signals for pulse oximeters can potentially be used to verify certain aspects of pulse oximeter
- 925 performance as discussed below. As discussed in ISO 80601-2-61, functional testers may not be
- able to represent all physiological and optical factors affecting pulse oximeter performance and
- 927 are not suitable for evaluating SpO₂ accuracy. When providing test reports for non-clinical

⁴⁹ For details on the Q-Submission Program, refer to the guidance "<u>Requests for Feedback and Meetings for Medical</u> <u>Device Submissions: The Q-Submission Program</u>."

928 testing using a patient simulator or functional tester, we recommend that manufacturers include a 929 justification for the methods used to perform the test and a rationale of how they provide signals 930 representative of the conditions being evaluated.

931

932

932 933

(1) SpO₂ accuracy for oximeters labeled for use in low perfusion conditions

<u>Significance</u>: Pulse oximeter performance may degrade under conditions of poor pulsatile signal
 strength which leads to low percent modulation. This degradation can cause a pulse oximeter to
 output inaccurate SpO₂ measurements. If the pulse oximeter is labeled for use in low perfusion
 conditions, testing should demonstrate device performance under such conditions.

938

939 <u>Recommendation</u>: We recommend that you conduct testing under conditions of low percent

940 modulation. One recommended method is to verify the SpO₂ accuracy under low percent

941 modulation conditions *in vitro* using a functional tester, set to the signal amplitude defined as

low perfusion for the system (e.g., 0.3% modulation). We recommend that a summary of the test

- 943 methods be provided in the labeling.
- 944
- 945

(2) Pulse rate accuracy

946 <u>Significance</u>: Pulse oximeters should demonstrate sufficient accuracy to be suitable for their
 947 intended use and to prevent adverse events related to incorrect measurements. If the system
 948 provides pulse rate measurements, testing should demonstrate device performance within

- 949 specification.
- 950

<u>Recommendation</u>: We recommend that you conduct testing on the specified pulse rate
 measurement range. One recommended method is to test your system on the bench (using a

952 inteastrement range. One recommended method is to test your system on the benefit (using a 953 functional tester) at the lowest pulse amplitude specified as "normal." We recommend that a 954 summary of the test methods be provided in the labeling.

- 955
- 956
- 950 957

(3) Pulse rate accuracy for oximeters labeled for use during motion conditions

958 <u>Significance</u>: Pulse oximeter performance may degrade under conditions of motion. This

959 degradation can cause a pulse oximeter to output inaccurate pulse rate measurements. If the pulse

960 oximeter is labeled for use during motion conditions, testing should demonstrate device

- 961 performance under motion conditions.
- 962

963 <u>Recommendation</u>: We recommend that all continuous (real-time monitoring and data archiving)

964 pulse oximeters be subject to motion testing. We also recommend non-continuous pulse

965 oximeters labeled for use in motion conditions be subject to motion testing. One recommended 966 approach is to use the same method used to demonstrate sufficient pulse rate accuracy generally,

967 as described in Section IV.N(2), but with motion incorporated. We recommend including a

Draft – Not for Implementation

968 description of the characteristics of each motion including amplitudes, types, and frequencies 969 selected for testing. We recommend that a summary of the test methods be provided in the 970 labeling. 971 972 (4) Pulse rate accuracy for oximeters labeled for use in low perfusion conditions 973 974 Significance: Pulse oximeter performance may degrade under conditions of poor pulsatile signal 975 strength. This degradation can cause a pulse oximeter to output inaccurate pulse rate 976 measurements. If the pulse oximeter is labeled for use in low perfusion conditions, testing should demonstrate device performance under low perfusion conditions. 977 978 979 Recommendation: We recommend that you conduct testing under conditions of low percent 980 modulation. A recommended approach is to use the same method used to demonstrate sufficient 981 pulse rate accuracy generally, as described in Section IV.N(2), with a functional tester, set to the 982 signal amplitude defined as low perfusion for the system (e.g., 0.3% modulation). We 983 recommend that a summary of the test methods be provided in the labeling. 984 (5) Alarms 985 986 Significance: Device operators rely on proper operation of alarms to alert them to take 987 appropriate actions in care of a patient or to resolve a device issue. Failure of a pulse oximeter to 988 activate an alarm can cause delayed response to abnormally high or low SpO₂ or pulse rate, if 989 applicable. 990 991 Recommendation: We recommend physiological alarms for all continuous real-time monitoring 992 pulse oximeters. We recommend that you address alarm-related clauses of the currently FDA-993 recognized version of ISO 80601-2-61 or an equivalent method for visual and audible alarms of 994 the monitor and any remote alarm unit. 995 (6) Display values, outputs and indicators 996 997 Significance: Device operators rely on device indicators and outputs to determine if the pulse 998 oximeter is functioning as intended. Degraded performance under conditions resulting in poor 999 signal quality can cause pulse oximeters to output inaccurate or outdated SpO₂ and pulse rate 1000 measurements. Testing should demonstrate the device provides an indication of potentially 1001 incorrect measurements and when measurements may not be current. 1002 1003 Recommendation: We recommend that the device provide an indicator of signal inadequacy. We 1004 also recommend the device provide an indicator that SpO₂ or pulse rate data is not current when 1005 the update period is greater than 30 seconds. You can also refer to the currently FDA-recognized

1005 the update period is greater than 30 seconds. You can also refer to the currently FDA-recognized 1006 version of ISO 80601-2-61 for additional considerations regarding data update period and signal

1007 inadequacy.

Draft – Not for Implementation

1008

1009 We recommend that you conduct appropriate testing of all the data outputs, measurement values,

1010 and indicators that the device incorporates (e.g., signal inadequacy, perfusion index, pulse 1011 amplitude, signal strength).

1012

1013

(7) Saturation pulse information signal, if applicable

1014 Significance: Device operators might rely on changes in auditory pitch to indicate a change in 1015 SpO₂. Failure of changes in auditory pitch to follow a change in SpO₂ can result in delayed 1016 response by a user to detect clinically meaningful changes in SpO₂.

1017

1018 Recommendation: If your device includes a variable-pitch auditory information signal to indicate

1019 the pulse signal, we recommend the pitch change follow the change in SpO₂ reading and be

1020 verified through testing (see also currently FDA-recognized version of ISO 80601-2-61).

1021

O. **Clinical Performance Testing** 1022

1023 Significance: Clinical studies are important to evaluate device safety and effectiveness for all 1024 pulse oximeter systems within the scope of this guidance and to assure non-disparate

1025 performance across populations with diverse skin pigmentation.

1026

1027 Recommendation: We recommend that you conduct a controlled desaturation laboratory study as 1028 described in Annex EE of ISO 80601-2-61 Second edition 2017-12 (Corrected version 2018-02) 1029 to determine SpO₂ accuracy. We also recommend that this study be used to demonstrate non-

disparate performance for new pulse oximeter systems.⁵⁰ In addition, for pulse oximeter systems 1030

1031 intended for use in pediatric populations younger than 12 years of age, we recommend that

1032 convenience arterial samples (SaO₂, SpO₂) be provided for pediatric populations younger than 12

1033 years of age to assure form and fit of sensor site and clinical performance.

1034

1035 We generally intend to consider alternatives to clinical testing to demonstrate substantial

1036 equivalence when the proposed alternatives are supported by an adequate scientific rationale. For

1037 example, when changes or modifications made do not affect the optical chain, signal processing

1038 path and SpO2 algorithm, then additional clinical studies might not be needed to demonstrate 1039 substantial equivalence.

1040

1041 If a clinical investigation is conducted to demonstrate substantial equivalence, i.e., conducted

- 1042 prior to obtaining 510(k) clearance of the device, it must comply with the Investigational Device
- 1043 Exemption (IDE) regulation, 21 CFR Part 812. Generally, we believe pulse oximeters addressed 1044
- by this guidance document would be considered non-significant risk devices; therefore, the study
- 1045 would likely be subject to the abbreviated requirements of 21 CFR 812.2(b). See the FDA
- 1046 guidance titled "Significant Risk and Nonsignificant Risk Medical Device Studies." In addition,

⁵⁰ FDA recognizes that a study in a simulated setting (i.e., controlled desaturation laboratory study) is likely to test individuals using a larger range of SaO₂ levels than a study collecting real world evidence from patients.

	sponsors of studies of a device intended to demonstrate substantial equivalence that are					
1048	conducted in the United States (US) are subject to the regulations governing institutional review					
1049	boards (21 CFR Part 56) and the protection of human subjects (21 CFR Part 50), including					
1050	requirements for informed consent.					
1051	-					
1052						
1053	devices, the requirements of 21 CFR 812.28 may apply. ⁵¹ 21 CFR 812.28(a) outlines the					
1054						
1055	support an IDE or a premarket submission. For more information, see the FDA guidance					
1056	"Acceptance of Clinical Data to Support Medical Device Applications and Submissions:					
1057	Frequently Asked Questions."					
1058						
1059	In some cases, "real-world data" (RWD) can be used, for example, to support expansion of an					
1060	indication or the evaluation of non-disparate performance for a device for which 510(k)					
1061	clearance has already been obtained. FDA encourages manufacturers to engage with the Agency					
1062	if they have questions on RWD. ⁵² Whether the collection of RWD for a legally marketed device					
1063	requires an IDE depends on the particular facts of the situation. For example, if a cleared device					
1064	is being used in the normal course of medical practice, an IDE would likely not be required. For					
1065	additional information regarding this topic, refer to the FDA guidance titled "Use of Real-World					
1066	Evidence to Support Regulatory Decision-Making for Medical Devices."					
1067						
1068	(1) Controlled Desaturation Laboratory Study					
11100	(1) Controlled Desaturation Laboratory Study					
1069	a. Purpose/Objective					
1069	a. Purpose/Objective					
1069 1070	a. Purpose/Objective The purpose of conducting an invasive controlled desaturation laboratory study is to verify the					
1069 1070 1071	a. Purpose/Objective The purpose of conducting an invasive controlled desaturation laboratory study is to verify the pulse oximeter system's SpO ₂ accuracy in comparison with reference measurements of					
1069 1070 1071 1072	a. Purpose/Objective The purpose of conducting an invasive controlled desaturation laboratory study is to verify the pulse oximeter system's SpO ₂ accuracy in comparison with reference measurements of functional SaO ₂ by a CO-oximeter and to demonstrate non-disparate performance across diverse					
1069 1070 1071 1072 1073	a. Purpose/Objective The purpose of conducting an invasive controlled desaturation laboratory study is to verify the pulse oximeter system's SpO ₂ accuracy in comparison with reference measurements of					
1069 1070 1071 1072 1073 1074	a. Purpose/Objective The purpose of conducting an invasive controlled desaturation laboratory study is to verify the pulse oximeter system's SpO ₂ accuracy in comparison with reference measurements of functional SaO ₂ by a CO-oximeter and to demonstrate non-disparate performance across diverse skin pigmentation.					
1069 1070 1071 1072 1073	a. Purpose/Objective The purpose of conducting an invasive controlled desaturation laboratory study is to verify the pulse oximeter system's SpO ₂ accuracy in comparison with reference measurements of functional SaO ₂ by a CO-oximeter and to demonstrate non-disparate performance across diverse					
1069 1070 1071 1072 1073 1074	a. Purpose/Objective The purpose of conducting an invasive controlled desaturation laboratory study is to verify the pulse oximeter system's SpO ₂ accuracy in comparison with reference measurements of functional SaO ₂ by a CO-oximeter and to demonstrate non-disparate performance across diverse skin pigmentation.					
1069 1070 1071 1072 1073 1074 1075	 a. Purpose/Objective The purpose of conducting an invasive controlled desaturation laboratory study is to verify the pulse oximeter system's SpO₂ accuracy in comparison with reference measurements of functional SaO₂ by a CO-oximeter and to demonstrate non-disparate performance across diverse skin pigmentation. b. Study Design 					
1069 1070 1071 1072 1073 1074 1075 1076	 a. Purpose/Objective The purpose of conducting an invasive controlled desaturation laboratory study is to verify the pulse oximeter system's SpO₂ accuracy in comparison with reference measurements of functional SaO₂ by a CO-oximeter and to demonstrate non-disparate performance across diverse skin pigmentation. b. Study Design We recommend that you conduct the study as described in Annex EE of ISO 80601-2-61 Second 					
1069 1070 1071 1072 1073 1074 1075 1076 1077	 a. Purpose/Objective The purpose of conducting an invasive controlled desaturation laboratory study is to verify the pulse oximeter system's SpO₂ accuracy in comparison with reference measurements of functional SaO₂ by a CO-oximeter and to demonstrate non-disparate performance across diverse skin pigmentation. b. Study Design We recommend that you conduct the study as described in Annex EE of ISO 80601-2-61 Second edition 2017-12 (Corrected version 2018-02) in a diversely pigmented group of 150 or more 					

⁵¹ 21 CFR 812.28 applies to relevant clinical investigations that enroll the first subject on or after February 21, 2019, and that support an IDE or a device marketing application or submission to FDA. ⁵² Manufacturers can seek input from the Agency via the Q-Submission Program. See FDA guidance "<u>Requests for</u>

Feedback and Meetings for Medical Device Submissions: The Q-Submission Program."

1081 1082 1083 1084	• Evaluate forehead pigmentation of study participants through visual assessment with the Monk Skin Tone (MST) scale ^{53, 54} – a ten level subjective skin color annotation with a high inter-rater reliability ⁵⁵ (see Appendix B for printing recommendations) defined in terms of CIELAB ⁵⁶ color space;
1085 1086	• Evaluate forehead pigmentation of study participants using colorimetry to determine L* and b* values, then calculating the Individual Typology Angle (ITA), which is defined
1087	as: ⁵⁷ ITA° = $\arctan\left(\frac{L^* - 50}{b^*}\right) * \frac{180}{\pi};$
1088	• Documenting information related to diversity in race and ethnicity during enrollment as
1089	described in Section III of FDA's draft guidance "Collection of Race and Ethnicity Data
1090	in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products";58
1091	• Allocate enrolled participants into three specific MST groups: 1-4, 5-7, 8-10, while
1092	ensuring the following:
1093	 at least 25% of participants fall within each MST group;
1094	◦ at least 50% of the participants in MST group 8-10 have an ITA \leq -50° at the
1095	forehead; and
1096	• in each MST group, at least 40% of participants are male, and at least 40% of
1097	participants are female.
1098	
1099	We recommend that you submit the protocol(s) used to assign MST and evaluate ITA in your
1100	premarket submission. For additional feedback, we recommend early engagement with the
1101	Agency through the Pre-Submission process as described in FDA's guidance "Requests for
1102	Feedback and Meetings for Medical Device Submissions: The Q-Submission Program" to
1103	discuss your proposed plan for MST assignment and ITA assessment in advance of conducting

- 1104 the study.
- 1105
- 1106 Additionally, we recommend measuring ITA values at the surface directly in contact with the
- 1107 sensor emitter. For fingertip sensors, to capture the widest variation in skin pigmentation
- applicable to sensor placement, we recommend evaluating sensor site ITA values (see yellow

⁵³ Heldreth CM, Monk EP, Clark AT, Schumann C, Eyee X, Ricco S. Which skin tone measures are the most inclusive? An investigation of skin tone measures for artificial intelligence. ACM Journal on Responsible Computing 1, no. 1 (2024): 1-21.

⁵⁴ It is important to note that MST, though validated for capturing race and ethnicity diversity in pigmentations within the US (see *ibid* Heldreth *et al.*), is not a proxy for racial and ethnic diversity.

⁵⁵ Schumann C, Olanubi GO, Wright A, Monk Jr. E, Heldreth C, Ricco S. 2024. Consensus and Subjectivity of Skin Tone Annotation for ML Fairness. In Proceedings of the 37th International Conference on Neural Information Processing Systems (NIPS '23). Article 1320: 30319-30348. Curran Associates Inc.


⁵⁶ For more information on standard colorimetry methods, refer to pp. 7-8 in the FDA's discussion paper "<u>Approach</u> for Improving the Performance Evaluation of Pulse Oximeter Devices Taking Into Consideration Skin Pigmentation, <u>Race and Ethnicity</u>."

⁵⁷ Ly BCK, Dyer EB, Feig JL, Chien AL, Del Bino S. Research Techniques Made Simple: Cutaneous Colorimetry: A Reliable Technique for Objective Skin Color Measurement. J Invest Derm. 2020,140(1):3-12.

⁵⁸ When final, this guidance will represent the FDA's current thinking on this topic.

Draft – Not for Implementation

1109 circle in Figure 1) at the mid-dorsal pigmented skin surface of the distal phalanx, proximal to the 1110 eponychium.



1138	premarket submission to the FDA as described in the FDA draft guidance " <u>Collection of Race</u>
1139 1140	and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products." ⁵⁹
1140	
1142 1143 1144	You should describe characteristics of your participant populations that could affect the results of the study, including:
1145	• Age;
1146	• Sex;
1147	 BMI;
1148	 Self/caregiver-reported ethnicity;
1149	 Self/caregiver-reported race;
1150	 Forehead MST and ITA values of each participant;
1150	 ITA value at the emitter sensor site placement;
1151	 Range of applicable dimension(s) of sensor site anatomy;
1152	
1155	 Range of percent modulation in study participants when obtaining data pairs (SaO₂, SpO₂); and
1155	• Percent of each MST group that tolerated full desaturation (down to SaO ₂ of 70%).
1156 1157 1158 1159 1160 1161	For more information regarding the evaluation and reporting of age, race, ethnicity and sex- specific data in medical device clinical studies, see FDA's guidances " <u>Evaluation of Sex-</u> <u>Specific Data in Medical Device Clinical Studies</u> " and " <u>Evaluation and Reporting of Age-, Race-</u> , and Ethnicity-Specific Data in Medical Device Clinical Studies."
1162	e. Protocol
1163 1164 1165 1166 1167 1168 1169 1170 1171	We recommend you provide ranges of percent modulation for study participants while obtaining data pairs (SaO ₂ , SpO ₂) and describe methods used to attain these values in your premarket submission. Additionally, we recommend conducting SpO ₂ accuracy testing under conditions of motion for all continuous (real-time monitoring and continuous data archiving) pulse oximeters and non-continuous pulse oximeters intended for use during motion conditions. We recommend including a description of the characteristics of each motion, if any, including amplitudes, types, and frequencies of motion selected for testing in your test report and justification of your method for the device's intended use.
1172	f. Effectiveness Endpoints and Data
1173 1174 1175	We recommend that an A _{rms} specification of less than 3% be shown with statistical significance, e.g., 95% CI. We recognize that accuracy is, among other things, a function of participant characteristics, application site and sensor geometry. Table 3 outlines the recommended A _{rms}

⁵⁹ When final, this guidance will represent the FDA's current thinking on this topic.

Draft – Not for Implementation

between measured values (SpO₂) and reference values (SaO₂) under normal conditions ranging 1176 1177 from 70% to 100% SpO₂. 1178 1179 Table 3: Typical Arms Specification by Sensor Type Arms with 95% CI* Sensor Type < 3 % Transmittance, wrap and clip < 3 % Ear clip Reflectance < 3%* 2-sided 95% confidence interval upper limit < 3%1180 g. Statistical Analysis Considerations 1181 1182 i. **Co-Primary Analyses** 1183 For pivotal controlled desaturation studies, we recommend co-primary analyses of the following 1184 performance metrics: 1185 1186 1. SpO_2 accuracy (A_{rms}) over all study participants. 1187 2. SpO_2 bias (mean error) as a function of SaO_2 and MST at the forehead. 1188 3. SpO_2 bias (mean error) as a function of SaO_2 and ITA measured at the skin surface in contact with the sensor emitter for the device. 1189 1190 ii. **Recommended Success Criteria** 1191 For the co-primary analyses, we recommend the following success criteria: 1192 1. Overall Accuracy: Arms is less than 3%. 1193 1194 2. Non-Disparate Performance Evaluation 1: Among pairwise comparisons of MST groups 1195 1-4, 5-7, and 8-10, the largest difference in SpO₂ bias is less than 3.5% for the interval 1196 $70\% \le \text{SaO}_2 \le 85\%$ and less than 1.5% for $85\% \le \text{SaO}_2 \le 100\%$. 1197 3. Non-Disparate Performance Evaluation 2: For a 100-point change in emitter sensor site 1198 ITA, the difference in SpO₂ bias is less than 3.5% for $70\% \le \text{SaO}_2 \le 85\%$ and less than 1.5% for $85\% < SaO_2 \le 100\%$. 1199 1200 1201 We recommend all three success criteria be shown with statistical significance, with either a 1-1202 sided hypothesis test at significance level of 2.5% (p-value of the null hypothesis is less than

Draft – Not for Implementation

2.5%) or a 2-sided 95% CI (limits of the 95% CI imply that the success criterion for the
 parameter is achieved).⁶⁰

1205

1212

1206 To visually characterize device performance (i.e., agreement, bias and uncertainty), FDA

1207 recommends that Bland Altman,⁶¹ modified Bland Altman,⁶² QQ,⁶³ and inverse prediction

1208 plots⁶⁴ should generally be provided in a premarket submission. FDA recommends that these

1209 plots be constructed with symbols or colors that code for MST group (1-4, 5-7, and 8-10). FDA

also recommends the Bland Altman and modified Bland Altman plots include the 95% limits of

1211 agreement.⁶⁵

iii. Sample Size

1213 The sample size of study participants should be the maximum of the sample sizes needed to

1214 obtain adequate power (80% or greater power is recommended) to meet each success criterion

1215 with statistical significance. For adequate power, FDA recommends a sample size of 150 or

1216 more participants who satisfy the enrollment criteria as described in Section IV.O(1)b.

1217 The appropriate number of study participants depends on pulse oximeter accuracy, data

1218 variability, and average number of paired repeated measures (SpO_2, SaO_2) per participant. We

1219 recommend an average of 20-24 simultaneous paired repeated measures per participant, a

1220 minimum of 17 and maximum of 30 pairs per participant, and at least 30% of pairs in each of the

1221 SaO₂ deciles, $70\% \le SaO_2 \le 80\%$, $80\% \le SaO_2 \le 90\%$, and $90\% \le SaO_2 \le 100\%$. When uncertainty

1222 exists concerning data variability or pulse oximeter accuracy, an adaptive study in which sample

size is adjusted based on accumulating data is potentially advantageous when feasible.⁶⁶

1224

iv. Analysis Population and Methods

1225 Performance metrics should be analyzed using the intention-to-diagnose (ITD) analysis

1226 population, defined as all participants enrolled into the study and all paired repeated measures of

1227 (SpO_2, SaO_2) even when one or both were invalid, non-evaluable, or missing. In other words,

1228 participants and paired repeated measures should not be excluded from the analysis population,

1229 whether the data are complete or not. You should report the number and proportion of

1230 incomplete data pairs.

⁶⁵ For calculation of 95% limits of agreement, see Bland JM, Altman DG. Agreement between methods of measurement with multiple observations per individual. J Biopharm Stat. 2007;17(4):571-82.

⁶⁶ Refer to the FDA guidance "<u>Adaptive Designs for Medical Device Clinical Studies</u>" for additional information on adaptive designs for a medical device clinical study.

⁶⁰ Ndikintum, N.K., & Rao, M. (2016). A Special Inference Problem in Repeated Measures Design—Test of Statistical Hypothesis on Accuracy Root Mean Square—Application to Pulse Oximetry Studies. *Statistics in Biopharmaceutical Research*, 8(1), 60-76.

⁶¹ Bland JM, Altman DG. Agreement between methods of measurement with multiple observations per individual. J Biopharm Stat. 2007;17(4):571-82.

⁶² For two measurements Y and X of the same quantity, the Bland-Altman plot is a plot of the difference D = Y - X vs. average A = (Y + X)/2. The modified Bland-Altman plot is a plot of D vs. X.

 $^{^{63}}$ For paired SpO₂ and SaO₂, a QQ plot of SpO₂ vs. SaO₂ is a scatterplot of the ordered values of SpO₂ vs. the ordered values of SaO₂.

⁶⁴ For a review of statistical methods for calculating inverse prediction intervals, see Greenwell BM, Schubert Kabban CM. investr: An R Package for Inverse Estimation. *The R Journal*. 2014 June; 6(1): 90-100.

1231	v. Missing Data
1232	
1233 1234	Efforts to reduce missing data We recommend you describe the efforts that you intend to use during the course of the study to
1234	minimize participant dropout and missing data.
1236	minimize participant diopout and missing data.
1237	Document reasons for missing data
1238	We recommend you identify the reasons for missing data if they occur, for example:
1239	Participant drop-out;
1240	• Participant has insufficient paired repeated measures (number or SaO ₂ span);
1241	Participant is excluded from analysis; and
1242	• Paired repeated measure is incomplete $(SpO_2 \text{ or } SaO_2 \text{ is invalid or missing})$.
1243	
1244	To support a complete and detailed accounting of all study participants, we recommend you
1245	collect complete information during the study. Without complete information, data may have
1246	been excluded from analysis, potentially introducing analysis bias, which could jeopardize the
1247 1248	conclusions that can be drawn about the substantial equivalence or safety and effectiveness of your device.
1249	your device.
1250	h. Grouping of sensors for testing
1251 1252	It may be appropriate to group certain sensors for testing if they are of similar design or equivalent performance. We consider sensors to be of similar design if they contain identical
1252	materials and electro-optical components and have equivalent sensor characteristics (e.g.,
1254	location of use). If you choose to group sensors for testing based on their similar design, we
1255	recommend that you indicate whether all sensors within each group contain identical materials
1256	and electro-optical components and describe the rationale for grouping. Generally, clip and
1257	adhesive sensors should not be grouped based on similar design because they differ in form, fit,
1258 1259	and functional specifications. If you choose to group sensors for testing based on equivalent performance, we recommend that you provide valid scientific evidence and statistical analysis to
1259	demonstrate that the results of testing are poolable.
1260	demonstrate that the results of testing are postable.
	(2) Additional considerations for pulse eximators intended for
1262	(2) Additional considerations for pulse oximeters intended for
1263	pediatric populations younger than 12 years of age
1264	
1265	If a pulse oximeter system is intended for use in pediatric populations younger than 12 years of
1266 1267	age, data supporting accuracy of clinical performance for the relevant pediatric subpopulation(s) and associated pathophysiologic state(s) should be considered. As stated earlier in this guidance,
1267	clinical performance testing of the pulse oximeter system (see Section IV.O(1)) in adult
1269	populations may not be sufficient to support clinical performance in certain pediatric subgroups
1270	such as neonates, infants, and children younger than 12 years of age due to significant

Draft – Not for Implementation

1271 differences in form and fit of the pulse oximeter sensor that may lead to differences in overall 1272 accuracy of the system.

1273

1274 If the device is intended for use in pediatric populations younger than 12 years of age, FDA 1275 recommends that manufacturers consider validating the performance in this population by:

1276 1277

1278

1279

1280

- (1) evaluating the performance of the pulse oximeter system using the pediatric sensor in adult participants across diverse skin pigmentation as described in Section IV.O(1)b; and
- (2) evaluating the performance in pediatric participants within the age range (and associated clinically relevant pathophysiologic state) specific to the indications for use and sensor placement.
- 1281 1282

1283 Regarding data in pediatric study participants, specifically for neonates, we recommend you

1284 report performance of pediatric sensors on adult participants as described above (Section

1285 IV.O(1)). If your device is intended for use with neonates, we recommend you provide testing on

1286 additional convenience arterial samples (see Annex EE of ISO 80601-2-61 Second edition 2017-1287

12 (Corrected version 2018-02)) collected on neonates to verify form, fit, and clinical 1288 performance. Manufacturers should also consider providing the additional convenience arterial

1289 samples collected on other pediatric subgroup(s) as well (e.g., infants, children in stable cyanotic

1290 and non-cyanotic states). If the sensor placement site in the pediatric subgroup is expected to

1291 have a larger variation of skin pigmentation than in the controlled desaturation adult study,

1292 manufacturers should consider including a skin pigmentation assessment, as described in Section

1293 IV.O(1)b, to assure diversity in skin pigmentation and non-disparate performance.

1294

1295 Though pediatric (e.g., neonatal) clinical studies are more representative of the intended use than 1296 controlled laboratory studies in adults, sampled data pairs may not span the entire SaO2 range

1297 verified in controlled adult studies and be drawn under uncontrolled conditions (e.g.,

1298 temperature, co-morbidities, non-simultaneous data pair). Nonetheless, we recommend you

1299 provide data and samples on enough participants equally distributed across the population

1300 subgroup and that you justify the sample size, and SaO2 range of data pairs (SaO2, SpO2).

1301 Additionally, we recommend that you include range of percent modulation of your study

1302 participants when obtaining data pairs. If your study includes enrollment by skin pigmentation 1303

(i.e., the sensor placement site in your pediatric subgroup(s) is expected to have a larger variation 1304 of skin pigmentation than in the controlled desaturation adult study), we recommend that you

1305 include reported race, ethnicity, MST measurement site, and MST values of each participant as

- 1306 well as ITA values at emitter sensor site for each relevant pediatric subgroup in your premarket submission.
- 1307
- 1308

1309 For additional feedback regarding validating pulse oximeter performance for patient populations

1310 younger than 12 years of age, we strongly recommend early engagement with the Agency

1311 through the Pre-Submission process, as described in the FDA guidance "Requests for Feedback

1312 and Meetings for Medical Device Submissions: The O-Submission Program," to discuss an

1313 approach and special considerations for supporting a pediatric indication for each device.

Draft – Not for Implementation

Note that FDA intends to update the recommendations for certain pediatric population(s) as more

1316 1317	information becomes available (e.g., CERSI clinical study with Stanford University). ⁶⁷
1318	V. Modifications (for previously 510(k)-cleared or
1319	authorized devices)
1320 1321 1322 1323 1324 1325	21 CFR 807.81(a)(3) provides that a device change or modification "that could significantly affect the safety or effectiveness of the device" or represents a "major change or modification in the intended use of the device" requires a new 510(k). ⁶⁸ In addition to the examples already referenced in this guidance (e.g., labeling related to non-disparate performance data), the changes or modifications listed below are examples of changes that are likely to require submission of a new 510(k), but note that this list is not exhaustive. For additional details, see FDA guidances
1326 1327	" <u>Deciding When to Submit a 510(k) for a Change to an Existing Device</u> " and " <u>Deciding When to</u> Submit a 510(k) for a Software Change to an Existing Device."
1328 1329 1330	Examples of such changes or modifications include:
1331 1332 1333 1334 1335	 Significant electro-optical sensor modifications (e.g., a new component or new bandage material in or near the light path, extensive re-design where a device is miniaturized). FDA generally considers this to be a significant change or modification in design because this change could significantly affect the safety and effectiveness of the device by affecting the optical chain or signal processing path.
1336 1337 1338 1339	• Significant SpO ₂ algorithm modifications. FDA generally considers this to be a significant change or modification in design. This type of change could significantly affect the safety and effectiveness of the device by affecting data processing and calculation of SpO ₂ .
1340 1341 1342 1343	• Significant changes to the input parameters of an SpO ₂ software function. FDA generally considers this to be a significant change or modification in design. This type of change could significantly affect the safety and effectiveness of the device by affecting data processing and calculation of SpO ₂ .

⁶⁷ For more information, see <u>https://www.fda.gov/science-research/advancing-regulatory-science/prospective-clinical-study-evaluate-accuracy-pulse-oximeters-children</u>

⁶⁸ Section 3308 of the Food and Drug Omnibus Reform Act of 2022 (FDORA), enacted as part of the Consolidated Appropriations Act, 2023, added section 515C "Predetermined Change Control Plans for Devices" to the FD&C Act (Pub. L. No. 117-328). Section 515C has provisions regarding predetermined change control plans (PCCPs) for devices requiring premarket approval or premarket notification. For example, section 515C states that supplemental applications (section 515C(a)) and new premarket notifications (section 515C(b)) are not required for a change to a device that would otherwise require a premarket approval supplement or new premarket notification if the change is consistent with a PCCP approved or cleared by FDA. Section 515C also states that FDA may require that a PCCP include labeling for safe and effective use of a device as such device changes pursuant to such plan, notification requirements if the device does not function as intended pursuant to such plan, and performance requirements for changes made under the plan. If you are interested in proposing a PCCP in your marketing submission, we encourage you to submit a Pre-Submission to engage in further discussion with CDRH. See FDA's guidance "Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program."

Draft – Not for Implementation

1344 1345 1346 1347 1348 1349	• Modifying the patient population, such as indicating the device for pediatric populations younger than 12 years of age (see Section IV.O(2)). FDA generally considers this to be a significant change or modification to the labeling and/or indications for use. This type of change could significantly affect the safety and effectivenessof the device by changing form, fit and clinical performance.
1350	If your device incorporates existing pulse oximetry technology that is legally marketed for the
1351	same intended use, and you have determined your device requires submission of a new 510(k),
1352	we recommend you provide the following:
1353	
1354	• 510(k) numbers for the submissions where each combination of oximeter, sensor, and
1355	cable were cleared for use together;
1356	• Report(s) of all relevant clinical studies (see Section IV.O) that support your current
1357	premarket submission and labeling (see Section IV.C);
1358	• Testing that demonstrates that SpO ₂ and pulse rate values calculated by the Original
1359	Equipment Manufacturer (OEM) system are not corrupted during communication to the
1360	host device. We recommend that you conduct the testing using a functional tester (see
1361	ISO 80601-2-61 for the definition and appropriate uses of a functional tester) to span the
1362	range of saturation and pulse rate values to assure communication between the sensor
1363	and the host module.
1364	

Appendix A. Example of Labeling for Pulse Oximeters 1366

1367

1374

1375

1381 1382

1383

1384

1385

1386 1387

1405

1368 This appendix provides an example of labeling that contains a representative sampling of the

- 1369 important types of warnings and directions for use that FDA recommends in Section IV.C. of
- 1370 this guidance. This appendix is not intended to encompass an exhaustive list of all warnings and directions for use.
- 1371 1372

1373 Warnings:

- Only your physician or health care provider can diagnose whether you are experiencing • hypoxemia (low blood oxygen levels).
- 1376 Seek timely attention if you experience signs and symptoms of low oxygen levels, and do • not rely solely on a pulse oximeter to assess your health condition or oxygen level. 1377
- If monitoring at home, pay attention to other signs or symptoms of low oxygen levels, 1378 1379 such as: 1380
 - Bluish coloring in the face, lips, or nails;
 - Shortness of breath, difficulty breathing, increase in respiratory rate or a cough that gets worse:
 - Restlessness and discomfort;
 - Chest pain or tightness; and
 - Fast or racing pulse rate.
 - Be aware that some patients with low oxygen levels may not show any or all of these symptoms.
- Do not adjust medications or therapy based on your pulse oximeter readings without first 1388 1389 consulting your health care provider since doing so may lead to harm.
- 1390 Pulse oximeters are not completely accurate and there is a range of uncertainty around the 1391 displayed SpO₂ value. Accuracy of SpO₂ generally decreases with decreasing true blood 1392 oxygenation. For example, a pulse oximeter saturation value of 90% may be indicative of 1393 an arterial blood oxygenation between 87% to 93% while a pulse oximeter saturation of 1394 80% may be indicative of an arterial blood oxygenation of 75% to 85%. Pulse oximeter 1395 readings should only be used as an estimate of arterial blood oxygenation.
- 1396 Differences in skin tones may affect the accuracy of oxygen level readings, particularly • 1397 when oxygen levels are very low. Consult your health care provider if you have questions 1398 or concerns about your readings.
- 1399 Changes or trends in measurements (e.g., decreasing SpO₂ values from 97% to 90%) may • 1400 be more meaningful than one single measurement (e.g., SpO₂ of 94%). Accuracy of this 1401 pulse oximeter is not typically verified below arterial blood oxygen saturation (SaO₂) 1402 levels of 70%.
- 1403 Some factors that may affect pulse oximetry accuracy include: • 1404
 - Lower blood oxygen saturations;
 - Low blood flow or pulsatility (poor circulation);
- High ambient light levels; 1406
- Excessive movement (including shivering); 1407
- 1408 o (cold) Skin temperature;

1409	 Nail polish, artificial nails, or tattoo ink;
1410	• Presence of intravascular dyes used for medical purposes (e.g., methylene blue);
1411	 Blood disorders like anemia (e.g., sickle cell disease);
1412	 Smoking;
1413	 Radio frequency interference;
1414	• Pulsations in the veins (these may be caused by valvular heart conditions or
1415	vascular access used for hemodialysis); and
1416	• Presence of abnormal hemoglobin (e.g., methemoglobin, carboxyhemoglobin).
1417	• Continuous wear over the maximum specified time may lead to adverse events (e.g.,
1418	breakdown of the skin, decreased blood flow to sensor site).
1419	• Continuous wear in certain locations (e.g., hand, foot, ankle) in younger populations (e.g.,
1420	infants, children) may interfere with normal activity and age-appropriate development,
1421	such as turning over, crawling, standing, and walking.
1422	• Alarms and alerts may cause sleep interruptions in those caring for and/or wearing the
1423	pulse oximeter.
1424	
1425	Directions for Use
1426	• Position the sensor (usually on the finger) below the mid-chest. Positioning the sensor
1427	above the level of the heart may reduce accuracy.
1428	• Usually, the ring or middle finger work best for fingertip pulse oximeters.
1429	• Place the sensor so that the path between each side is straight and without any
1430	obstruction (e.g., a ring, tattoo).
1431	• For spot-check use, wait for 30 seconds or more of stable SpO ₂ reading.
1432	• If percent modulation is displayed on the pulse oximeter, pay attention whether it is
1433	within the value(s) provided to consider whether your estimated oxygen level (SpO ₂) is
1434	accurate.
1435	• Choose a probe location where the skin is intact, healthy, and does not have any cuts,
1436	eczema, infections, swelling or other problems such as poor circulation.
1437	• Remove or reposition the sensor every four hours [or manufacturer's maximum specified
1438	time] or if it causes discomfort or skin changes at the site of application.
1439	• In between uses, clean your pulse oximeter using the appropriate materials [per
1440	manufacturer's instructions].
1441	
1442	
1443	
1444	
1445	
1446	
1447	

1448

Appendix B. Considerations for Printing Monk Skin Tone Color Charts

1451

A scale that is well-defined in a standardized color space, such as CIELAB,⁶⁹ should be used to support evaluation of non-disparate performance as described in Section IV.O(1)b of this document. One of the options available is the Monk Skin Tone (MST) scale. FDA recommends evaluating skin tone according to the MST approach, where color charts are based on the following L*a*b* values in Table B1.⁷⁰ We recommend that color charts be professionally printed with a calibrated printer on appropriate paper. Color chart accuracy should be verified with a calibrated spectrophotometer.

- 1459
- 1460
- 1461

Table B1: MST Scale as Defined in CIELAB Color Space

MST Level	L*	a*	b*
1	94.2	1.5	5.4
2	92.3	2.1	7.3
3	93.1	0.2	14.2
4	87.6	0.5	17.7
5	77.9	3.5	23.1
6	55.1	7.8	26.7
7	42.5	12.3	20.5
8	30.7	11.7	13.3
9	21.1	2.7	6.0
10	14.6	1.5	3.5

1462

 ⁶⁹ See FDA-recognized consensus standard ISO/CIE 11664-4 *Colorimetry – Part 4: CIE 1976 L*a*b* colour space.* ⁷⁰ See https://skintone.google for additional information (last accessed on July 12, 2024).